US20080311182A1 - Multistage delivery of active agents - Google Patents

Multistage delivery of active agents Download PDF

Info

Publication number
US20080311182A1
US20080311182A1 US11/836,004 US83600407A US2008311182A1 US 20080311182 A1 US20080311182 A1 US 20080311182A1 US 83600407 A US83600407 A US 83600407A US 2008311182 A1 US2008311182 A1 US 2008311182A1
Authority
US
United States
Prior art keywords
stage
particle
particles
stage particle
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/836,004
Other languages
English (en)
Inventor
Mauro Ferrari
Ennio Tasciotti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
University of Texas System
Original Assignee
Ohio State University Research Foundation
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation, University of Texas System filed Critical Ohio State University Research Foundation
Priority to US11/836,004 priority Critical patent/US20080311182A1/en
Assigned to THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM reassignment THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FERRARI, MAURO, SAKAMOTO, JASON, TASCIOTTI, ENNIO
Assigned to US GOVERNMENT - SECRETARY FOR THE ARMY reassignment US GOVERNMENT - SECRETARY FOR THE ARMY CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER HOUSTON
Priority to PCT/US2008/061775 priority patent/WO2008134637A1/en
Priority to EP08780571A priority patent/EP2150493A1/en
Priority to JP2010506558A priority patent/JP2010526652A/ja
Priority to CN2008800220199A priority patent/CN101778796B/zh
Priority to KR1020097024739A priority patent/KR20100051591A/ko
Priority to US12/110,515 priority patent/US8920625B2/en
Priority to AU2008245496A priority patent/AU2008245496A1/en
Priority to CA2685544A priority patent/CA2685544C/en
Publication of US20080311182A1 publication Critical patent/US20080311182A1/en
Assigned to NASA reassignment NASA CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: TEXAS HEALTH SCIENCE CENTER AT HOUSTON, UNIVERSITY OF
Assigned to NASA reassignment NASA CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON
Priority to JP2012196070A priority patent/JP2013034991A/ja
Priority to US14/538,065 priority patent/US10253424B2/en
Priority to US14/725,570 priority patent/US10143658B2/en
Priority to US16/158,644 priority patent/US20190111000A1/en
Priority to US17/368,401 priority patent/US20210338593A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Definitions

  • the present inventions relate generally to the field of nanotechnology and, in particular, to compositions utilizing micro and/or nanoparticles for delivery active agents, such as therapeutic and imaging agents, and methods of making and methods of using such compositions.
  • an active agent such as a therapeutic or imaging agent
  • an active agent should travel through vasculature, reach the intended target at full concentration, then act selectively on diseased cells and tissues only, without creating undesired side effects.
  • a therapeutic or imaging agent should travel through vasculature, reach the intended target at full concentration, then act selectively on diseased cells and tissues only, without creating undesired side effects.
  • Nano-scale and micro-scale drug delivery systems are promising candidates for providing solutions to the problem of optimizing therapeutic index for a treatment, i.e. maximizing efficacy, while reducing health-adverse side effects.
  • Even modest amounts of progress towards this goal have historically engendered substantial benefits across multiple fields of medicine, with the translatability from, for example, a subfield of oncology to a field as distant as the treatment of infectious disease being granted by the fact that the progresses had a single common denominator in the underlying technological platform.
  • liposomes the first nanovector therapy to reach health-care fruition over 10 years ago for treatment of Kaposi's sarcoma, have also yielded advances in the treatment of breast and ovarian cancers, as well as fungal infections.
  • nanovector platforms include polymer-based platforms, dendrimers, gold nano-shells, semiconductor nano-crystals, fullerenes, biologically derived nano-constructs, silicon- and silica-based nanosystems and superparamagnetic nanoparticulates are described in the literature 49-75 .
  • composition which comprises at least one first stage particle that is a micro or nanoparticle and that has (i) a body, (ii) at least one surface, and (iii) at least one reservoir inside the body, such that the reservoir contains at least one second stage particle that comprises at least one active agent.
  • a method comprising administering to a subject a composition comprising: at least one first stage particle, that is a micro or nanoparticle and that has (i) a body, (ii) at least one surface and (iii) at least one reservoir inside the body, such that the reservoir contains at least one second stage particle that comprises at least one active agent.
  • a method of making a multistage delivery system comprises (A) providing at least one first stage particle, that is a micro or nanoparticle and that has (i) a body, (ii) at least one surface (iii) at least one reservoir inside the body; (B) providing at least one second stage particle and (C) loading the at least one second stage particle inside the reservoir of the first stage particle.
  • FIG. 1 illustrates a multistage delivery vehicle, in accordance with an embodiment of the invention.
  • the first stage particle contains inside second stage particles.
  • the second stage particles may comprise at least one active agent, such as a therapeutic agent or an imaging agent.
  • the first stage particle also contains inside an additional agent, such as a permeation enhancer or an additional active agent, which may be an imaging agent or a therapeutic agent.
  • the second stage particles contain third stage particles.
  • FIG. 2 illustrates the principle of operation of a multistage delivery vehicle administered intravascularly, in accordance with an embodiment.
  • the first stage particle localizes at the targeted vasculature location. Upon the localization, the particle releases permeation enhancers that generate a fenestration in the vasculature.
  • Second stage particles carry targeting moieties, such as antibodies. The second stage particles may permeate through the fenestration and target specific cells, that carry surface marker antigens, using the antibodies.
  • FIG. 3 Panel A, depicts time dependence of amino and carboxy modified quantum dots (q-dots) in APTES modified “large pore” LP and “small pore” nanoporous silicon first stage particle.
  • FIG. 3 Panel B, demonstrates an effect of second stage PEG-FITC-SWNT nanoparticles concentration on their loading into nanoporous silicon first stage particles.
  • Y-axis reads mean fluorescence.
  • FIG. 4 Panels A-D, demonstrate time dynamics of second stage nanoparticles loading into nanoporous silicon first stage particles.
  • Panel A for “large pore” (LP) oxidized silicon first stage particles
  • Panel B for LP APTES modified silicon first stage particles
  • Panel C for “small pore” (SP) oxidized silicon first stage particle
  • Panel D for SP APTES modifies silicon first stage particles.
  • Y-axis reads mean fluorescence.
  • FIG. 5 demonstrates time dynamics of second stage nanoparticles release from LP oxidized nanoporous silicon first stage particles (Panel A) and LP APTES modified nanoporous silicon first stage particles (Panel B).
  • Y-axis reads released payload (%).
  • FIG. 6A Panel A, presents the concentration effect of loading carboxy modified quantum dots and FITC-conjugated single wall carbon nanotubes (SWNTs). Y axis in Panel A reads mean fluorescence (%). FIG. 6A , Panel B, demonstrates fluorescence quenching of Fluorescein Isothiocyanate (FITC) conjugated Single Wall Carbon Nanotubes (SWNT).
  • FITC Fluorescein Isothiocyanate
  • FIG. 6B relates to optimization of chemical condition for loading of second stage particles into nanoporous silicon particles.
  • Nanoporous silicon particles were mixed with second stage nanoparticles (Q-dots in FIG. 6B , Panel C and Panel D; PEG-FITC-SWNTs in Panel E and Panel F) in the presence of increasing concentration of TRIS.
  • High concentration of TRIS helped in increasing the amount of Q-dots loaded into the first stage silicon particles (Panel C and Panel D).
  • loading efficiency of PEG-FITC-SWNTs reached its peak at 20 Mm TRIS and then decreased at higher TRIS concentrations, Panel E and Panel F.
  • Y axis in Panels B-F reads mean fluorescence.
  • FIG. 7 demonstrates data for loading and release respectively FITC conjugated with SWNT second stage particles into LP nanoporous silicon first stage particles.
  • Panel A presents load columns, corresponding to the amount of FITC-SWNT initially loaded in the nanoporous silicon first stage particles after exposure to a FITC-SWNT solution prior to washing. Wash columns in Panel A corresponds to the amount of FITC-SWNT after washing the first stage particles.
  • the actual load of the FITC-SWNT in the first stage particles is the amount of FITC-SWNT retained in the first stage particles after washing, i.e., a difference between the respective values in the load column and in the wash column.
  • Panel B shows data for release of FITC-SWNT from the first stage particles over time.
  • the total amount of FITC-SWNT released from the first stage particles over time i.e., a sum of all the columns in Panel B, substantially matches the difference between respective load and wash columns in Panel A.
  • Y axis in Panels A and B reads amount of FITC-SWNTs (ng).
  • FIGS. 8A-B present data for lipid based second stage particles loading into nanoporous silicon first stage particles.
  • Panels A-C show data for cationic and neutral liposomes loaded into 1 micron nanoporous silicon first stage particles.
  • Panel A shows confocal microscopy images of neutral liposomes (left) and cationic liposomes (right).
  • Panels B and C present respectively FACS analysis and Excel quantification of neutral and cationic liposome loading into 1 micron nanoporous silicon first stage particles.
  • Y axis in Panel B reads particle number and Y axis in Panel C reads green fluorescence (logarithmic values).
  • FIG. 8A Panels A-C show data for cationic and neutral liposomes loaded into 1 micron nanoporous silicon first stage particles.
  • Panel A shows confocal microscopy images of neutral liposomes (left) and cationic liposomes (right).
  • Panels B and C present respectively FACS analysis and Excel quant
  • Panel D shows time dynamics of loading liposomes containing Alexa 555 labeled SiRNA into 3.5 micron nanoporous oxidized silicon first stage particles.
  • Y axis in Panel D reads mean fluorescence.
  • Panel E and Panel F present fluorescent microscopy images visualizing fluorescence associated with liposomes containing Alexa 555 labeled SiRNA into 3.5 micron nanoporous silicon first stage particles.
  • FIG. 9 Panels A-D, demonstrate Scanning Electron Microscopy (SEM) images of “large pore” (LP) nanoporous silicon first stage particles.
  • FIG. 10 Panels A-D, demonstrate Scanning Electron Microscopy (SEM) images of “small pore” (SP) nanoporous silicon first stage particles.
  • FIG. 11 Panels A-D, demonstrate degradation of nanoporous silicon particles measured using Z2 Coulter® Particle Counter.
  • Y axis in Panels A and B reads number of particles.
  • Y axis in Panels C and D reads volume of particles.
  • FIGS. 12A-B demonstrate degradation of nanoporous silicon particles measured using Inductive Coupled Plasma—Atomic Emission Spectrometry.
  • FIG. 12A Panel A, for LP oxidized silicon particles; Panel B for SP oxidized silicon particles; FIG. 12B , Panel C, for LP APTES modified silicon particles.
  • Panel D for SP APTES modified silicon particles.
  • Y axis in FIGS. 12A-12B reads concentration of silicon (ng/mL).
  • FIG. 13 demonstrates biocompatability of nanoporous silicon first stage particles by presenting bright field microscopy images of selected nanoporous silicon particles and Human Umbelical Vein Endothelial Cells (HUVEC) cells.
  • Panel A demonstrates images for small pore oxidized silicon nanoparticles
  • Panel B demonstrates images for small pore APTES modified silicon nanoparticles
  • Panel C demonstrates images for large pore oxidized silicon nanoparticles
  • Panel D demonstrates images for large pore APTES modified silicon nanoparticles.
  • first image day 0 (2 hrs after particles addition), second image day 1; third image day 2; fourth image day 3.
  • FIGS. 14A-B demonstrate biocompatibility of nanoporous silicon particles by presenting data for Lactate Dehydrogenase (LDH) toxicity assay on HUVEC cells incubated with nanoporous silicon nanoparticles.
  • LDH Lactate Dehydrogenase
  • FIGS. 15A-B present data for MTT proliferation assay on HUVEC cells incubated with nanoporous silicon nanoparticles.
  • Y axis in FIG. 15A , Panels A-B and FIG. 15B , Panels C-F reads absorbance at 570 nm.
  • FIG. 16 Panels A-C, present FACS 3D Profiles of HUVEC cells incubated with Nanoporous Silicon Particles and analyzed for their size and shape.
  • FIG. 17A-17D present FACS 3D Profiles of HUVEC cells incubated with Nanoporous Silicon First Stage Particles and stained with propidium iodide to study cell cycle.
  • FIGS. 18A-C present statistical analysis of different phases of the cell cycle of cells exposed to nanoporous silicon first stage particles.
  • Y axis in FIG. 18A , Panels A-C, FIG. 18B , Panels D-G, and FIG. 18C , Panels H-K reads % of total cell population.
  • FIG. 19 Panels a and b, demonstrate SEM images of a porous silicon particle.
  • the size and shape of the LP and SP particles are the same, the size and structure of the pores are significantly different.
  • FIG. 20 presents results of flow cytometric and fluorescence microscopy analysis of loading of fluorescently labeled Q-dots and PEG-FITC-SWNTs into nanoporous silicon particles.
  • An increase in the amount of nanoparticles in the loading solution resulted in an increase in the mean fluorescence of silicon particles ( ⁇ LP APTES+Carboxyl Q-dots ⁇ LP oxidized+Amino Q-dots ⁇ SP APTES+Carboxyl Q-dots ⁇ SP oxidized+Amino Q-dots) measured by flow cytometry (Panels A and B).
  • Fluorescent microscopy (Panels C and D) confirmed that the fluorescence associated to first stage particle was dimmer when the amount of nanoparticles used was lower.
  • Y axis in Panels A and B reads mean fluorescence.
  • FIG. 21 presents time dependent loading and releasing of second stage particles in nanoporous silicon first stage particles.
  • LP oxidized (Panel a) LP APTES (Panel b)
  • SP oxidized (Panel c) SP APTES (Panel d)
  • second stage nanoparticles ⁇ Carboxyl q-dots, ⁇ Amino q-dots, ⁇ PEG-FITC-SWNTs
  • Histograms in Panels e-h represent a percentage of second stage particles released from the first stage silicon particles with the passage of time.
  • FIG. 22 presents confocal microscopy images demonstrating concentrated loading of Q-dots in a highly porous region of the back side of silicon particle.
  • Panel a shows confocal microscopy images reconstructed in a series of 3 dimensional projections showing a single porous silicon particle rotated to display different vantage points.
  • Panel b shows computer generated 3 dimensional models illustrating the rotation of the particle as shown in Panel a.
  • FIGS. 23A-23C illustrate simultaneous loading and releasing of Q-dots and PEG-FITC-SWNTs second stage particles in nanoporous silicon first stage particles.
  • Flow cytometry analysis showing background green and red fluorescence of LP APTES particles (Unloaded; FIG. 23A , Panel A and Panel B respectively) and the shifts of the fluorescence signals after the incubation with PEG-FITC-SWNTs (+SWNTs), Q-dots (+Q-dots) and both (+Q-dots+SWNTs).
  • Flow cytometry analysis show that PEG-FITC-SWNTs load rapidly and stabilize, while Q-dots gradually load before reaching a plateau, see FIG. 23B , Panel C.
  • FIG. 23 B Panel D.
  • Confocal microscopy images show the localization of the Q-dots (red) and PEG-FITC-SWNTs (green) in a single porous silicon particle.
  • FIG. 23C Panel E, Panel F and Panel G show bright field, green and red fluorescence respectively, while Panel h shows overlay of the 3 channels are shown. Yellow display showed co-localization of green and red fluorescent signals.
  • Y axis in FIG. 23 B, Panel D reads mean fluorescence; Y axis in Panel D reads released payload.
  • FIG. 24 Panels a-m, show fluorescent spectroscopy images related to incubating nanoporous silicon particles loaded with second stage particles with HUVEC cells for 1 h at 37 C.
  • the second stage particles are Q-dots; in Panels e-h, the second stage particles are PEG-FITC-SWNTs; in Panels j-m, the second stage particles are Q-dots and PEG-FITC-SWNTs.
  • FIG. 24 Panels d, h and m are bright field images showing the details of particle morphology.
  • FIG. 25 Panels A-C, present computer models representing the three major physical, chemical and electrostatic mechanisms responsible for loading and release of second stage nanoparticles in first stage silicon carrier.
  • Size Dependency The size of the pores determines the type of nanoparticles that are preferably loaded into the silicon particle.
  • Dose Dependency A larger number of nanoparticles in the loading solution cause an increase in the number of particles that are loaded into the pores.
  • Charge Dependency Compatibly charged nanoparticles will be attracted into the pores, whereas incompatible charges will partially repel the nanoparticles and thus prevent them to enter the pores.
  • FIG. 26 Panels A-B, present data for liposomes containing SiRNA loaded into nanoporous silicon first stage particles.
  • Panel A Alexa 555 fluorescently labeled siRNAs were encapsulated into nano-liposomes and loaded into the 1st stage nano-vectors. The data show that the fluorescence associated with the porous Silicon carrier increased with the amount of nanoliposomes.
  • Y axis reads mean fluorescence in Panel A.
  • FIG. 26 , Panel B presents a graph showing relative amount of liposomes released from first stage nanoporous silicon particles. Y axis reads % of total amount of released liposomes.
  • the assembled multistage particles were incubated with 10% fetal bovine serum (pH 7.4) and release of nanoliposomes from 1st stage particles was followed along time using fluorimetry. Complete unloading was achieved in about 36 h.
  • FIG. 27 demonstrates optimization of physical condition for loading of quantum dots and PEG-FITC-SWNTs.
  • Y axis in Panel a and Panel b reads mean fluorescence.
  • Porous silicon particles were desiccated in a desiccator over night and then mixed with the loading solution containing the second stage nanoparticles. Loading efficiency in dry condition was not significantly different than loading efficiency in a wet environment (p value>0.5).
  • Biochemical environment of the target body site refers to one or more intrinsic physiological conditions at the target site, such as pH, salt conditions, temperature, or the presence of target specific moieties, effective to initiate and promote release of the particle content.
  • Biodegradable refers to a material that may dissolve or degrade in a physiological medium or a biocompatible polymeric material that may be degraded under physiological conditions by physiological enzymes and/or chemical conditions.
  • “Mucoadhesive” refers to the capability of the particle to adhere to the mucosal layer, which lines the entire surface in the small and large intestine. Adherence is mediated by ligands grafted to the surface of the particles, which bind to chemical receptors present in mucin or the surface of the intestinal epithelial cells.
  • Targeting moiety is any factor that may facilitate targeting of a specific site by a particle.
  • the targeting moiety may be a chemical targeting moiety, a physical targeting moiety, a geometrical targeting moiety or a combination thereof.
  • the chemical targeting moiety may be a chemical group or molecule on a surface of the particle; the physical targeting moiety may be a specific physical property of the particle, such as a surface such or hydrophobicity; the geometrical targeting moiety includes a size and a shape of the particle.
  • Microparticle means a particle having a maximum characteristic size from 1 micron to 1000 microns, or from 1 micron to 100 microns. “Nanoparticle” means a particle having a maximum characteristic size of less than 1 micron.
  • Biocompatible refers to a material that, when exposed to living cells, will support an appropriate cellular activity of the cells without causing an undesirable effect in the cells such as a change in a living cycle of the cells; a change in a proliferation rate of the cells and a cytotoxic effect.
  • a composition that includes two or more stages of particles, such that particles of a later stage (smaller size particles) are contained in particles of an earlier stage (larger particles), will potentially provide one or more advantages for treating, preventing and/imaging a physiological condition, such as a disease, in a subject, which may be any animal with a blood system (e.g., the subject may be a warm blooded animal, such as mammal including human being).
  • a physiological condition such as a disease
  • a subject which may be any animal with a blood system (e.g., the subject may be a warm blooded animal, such as mammal including human being).
  • an active agent such as a therapeutic agent or an imaging agent, is preferentially delivered and/or localized to a particular target site in a body of a subject.
  • Preferential delivery and/or localization means that an amount or concentration of the active agent delivered to and/or localized at the target site is higher than an amount or concentration of the active agent delivered to and/or localized at other sites in the body of the subject; (2) a multistage composition sequentially overcomes multiple biological barriers in a body of the subject; and (3) a multistage composition allows for simultaneous delivery and localization at the same or different target site of multiple active agents.
  • an active agent such as a therapeutic or imaging agent, formulated conventionally or in a nanovector, encounters a multiplicity of biological barriers that adversely impact the agent's ability to reach an intended target at a desired concentration.
  • the biological barrier may be, for example, an epithelial or endothelial barrier, such as a blood-brain barrier or intestinal lumen endothelium, that are based on tight junctions, that prevent or limit para-cellular transport of an active agent.
  • Each of the endo/epithelial barrier includes a plurality of sequential subbarriers, such as tight junction barriers, that owe their molecular discrimination to one or more zonula occluden proteins, and one or more additional biological membranes, such as vascular endothelial basement membrane or a musocal layer of the intestinal endothelium.
  • Cells of the reticulo-endothelial system may also act as a biological barrier against an active agent encapsulated inside nanoparticles, as such cells sequester/uptake the nanoparticles.
  • the biological barrier may be also represented by a cell membrane or a nuclear membrane in a cell that an active agent has to come through.
  • a delivery vehicle that, in embodiments, acts in multiple stages.
  • Each stage of the vehicle is defined by a particle having a separate intended function, which may be different from an intended function of a particle of another stage.
  • a particle of one stage is designed to target a specific body site, which may be different from a site targeted by a particle of another stage, and thus to overcome or bypass a specific biological barrier, which is different from a biological barrier being overcome or bypassed by a particle of another stage.
  • a particle of each subsequent stage is contained inside a particle of an immediately preceding stage.
  • a particle of any particular stage may contain an active agent, such as a therapeutic agent or an imaging agent, intended for use at this particular stage.
  • a particle of the last stage is an active agent formulated as a nanoparticle or alternatively the last stage particle contains the active agent inside, while a particle of any earlier stage per se may or may not comprise an active agent.
  • a particle of each stage in addition to targeting a specific body site, is designed in such a way that it is capable to perform targeted release of its content.
  • the number and type of stages in the multistage delivery vehicle depends on several parameters, including administration route and an intended final target for the active agent. An embodiment of a multistage delivery vehicle is illustrated on FIG. 1 .
  • the particle of the first stage is a micro or nanoparticle.
  • the first stage particle has a characteristic size of at least 500 microns or at least 1 mm.
  • Such a particle may be configured to contain inside at least one micro or nanoparticle, which in turn may contain inside at least one particle of a smaller size.
  • the first stage particle is any particle that is capable of containing inside particles of a smaller size.
  • the first stage particle is a top-down fabricated particle, i.e., a particle prepared by top-down microfabrication or nanofabrication methods, such as photolithography, electron beam lithography, X-ray lithography, deep UV lithography or nanoprint lithography.
  • top-down fabrication methods such as photolithography, electron beam lithography, X-ray lithography, deep UV lithography or nanoprint lithography.
  • the particle of the first stage may be configured to overcome at least one of the following biological barriers: a hemo-rheology barrier, a Reticulo-Endothelial System barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier or a combination thereof.
  • biological barriers a hemo-rheology barrier, a Reticulo-Endothelial System barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier or a combination thereof.
  • the first stage particle may have a body that is defined by a size and a shape of the particle and one or more reservoirs inside the body.
  • One or more second stage particles may be contained inside the reservoir.
  • the body of the first stage particle comprises any appropriate material.
  • the material of the body of the first stage particle is biocompatible.
  • the body of the first stage particle comprises an oxide material such as silicon oxide, aluminum oxide, titanium oxide, or iron oxide; a semiconductor material, such as silicon; a polymer or a polymer oxide material; or a ceramic material.
  • the body of the first stage particle comprises a biodegradable material, such as, for example, nanoporous silicon.
  • the biodegradable material may be such that it degrades when exposed to a physiological medium such as silicic acid.
  • a material of the body of the first stage particle is substantially the same in different regions of the body.
  • the shape of the first stage particle may depend on the administration route. For example, the shape may be configured to maximize the contact between the first stage particle and a surface of the target site, such as endothelium surface for intravascular administration or intestinal epithelium for oral administration. Accordingly, for oral and intravascular administration, the first stage particle may have a selected non-spherical shape configured to maximize the contact between the particle and endothelium surface. Examples of appropriate shapes include, but are not limited to, an oblate spheroid or a disc. For pulmonary administration, i.e., administration to lungs of the subject, the first stage particles may also have a selected non-spherical shape configured to maximize a contact between the particle and one of the epithelial tissues in lungs.
  • the first stage particle may also have a spicular shape, which may facilitate entering of the particle from the lungs into a body tissue, not necessarily through the blood circulation.
  • a maximum characteristic size of the particle e.g., a diameter for a disc-shaped particle
  • a radius of the smallest capillary In humans, such a radius is about 4 or 5 microns. Accordingly, the maximum characteristic size of the particle are, in some embodiments, less than about 3 microns, less than about 2 microns or less than about 1 micron.
  • the maximum characteristic size of the first stage particle is from 500 nm to 3 microns, or from 700 nm to 2 microns. Yet in some embodiments for intravascular administration in oncological applications, the maximum characteristic size of the first stage particle is such that the first stage particle could localize at the targeted vasculature site without penetrating a fenestration in vascular cancer endothelium. For such applications, the maximum characteristic size of the first stage particle is greater than about 100 nm, or greater than about 150 nm, or greater than about 200 nm.
  • the size of the first stage particle is such so that the particle may penetrate the fenestration. Accordingly, the maximum characteristic size in such applications is preferably less than about 200 nm, or less than about 150 nm, or less than about 200 nm. In some embodiments, one may select a size of the first stage particle that is selected to be a critical radius of normal non-fenestrated vasculature for targeting fenestrated vasculature as detailed in PCT patent application No. PCT/US2006/038916 “Methods and Compositions for Targeting Fenestrated Vasculature” filed Sep. 27, 2006 to Paolo Decuzzi and Mauro Ferrari.
  • the first stage particle For oral administration, it may be preferable to use the first stage particle that has a maximum characteristic size greater than about 2 microns or greater than about 5 microns or greater than about 10 microns.
  • One advantage of using the first stage particle of such size for oral administration is that such particle may be too large to be endocytosed by intestinal epithelial cells.
  • the endocytosis by intestinal epithelial cells has at least two potential disadvantages: 1) the content of the first stage particle may be deactivated as it is processed by the endothelial cell before it reaches the desired target; 2) the potential toxicity of particular carrier, e.g. of the material of the particle, is of greater concern if it is endocytosed than if it is cleared through the gastrointestinal tract.
  • the first stage particle has a size ranging from 500 microns to several centimeters, or from 1 mm to 2 cm.
  • the maximum characteristic size of the first stage particle is preferably less than about 20 microns but greater than about 5 microns, if a targeted site is located in the lungs' air passages.
  • the maximum characteristic site may be less than about 5 microns.
  • a characteristic size of the first stage particle is from 50 microns to 1 mm; or from 100 microns to 1 mm.
  • One of the functions of the first stage particle is localization at a particular target site.
  • target site may be a particular vasculature site.
  • the targeted vasculature site may be a tumor vasculature, such as angiogenesis vasculature, coopted vasculature or renormalized vasculature.
  • the localization of the first stage particle at the targeted site may be facilitated by geometrical factors, such as the size and the shape of the particle.
  • the localization at the targeted site may be also facilitated by one or more recognition factors on the surface of the first stage particle.
  • the recognition factor may be a chemical targeting moiety, such as a dendrimer, an antibody, an aptamer, which may be a thioaptamer, a ligand or a biomolecule that binds a particular receptor on the targeted site.
  • the chemical moiety may comprise one or more mucoadhesive ligands, as described in Table 1 of U.S. Pat. No. 6,355,270.
  • the selectivity of the targeting may be tuned by changing chemical moieties of the surface of the particles.
  • coopted vasculature is specifically targetted using antibodies to angiopoietin 2; angiogenic vasculature is recognized using antibodies to vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGFb) or endothelial markers such as ⁇ v ⁇ 3 integrins, while renormalized vasculature are recognized using carcinoembionic antigen-related vell adhesion molecule 1 (CEACAM1), endothelin-B receptor (ET-B), vascular endothelial growth factor inhibitors gravin/AKAP12, a scallofldoing protein for protein kinase A and protein kinase C, see, e.g., Robert S. Korbel “Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?”, Science 26 May 2006, vol 312, no. 5777, 1171-1175.
  • the binding between the first stage particle and the molecular marker of the targeted vasculature site should be sufficiently strong to overcome the drag force exerted by the flowing blood.
  • This objective may be satisfied by having a relatively large planar surface area for specific binding and a relatively low profile in a capillary's blood flow space, i.e., by having the particle of the selected non-spherical shape, such as an oblate spheroid or a disc.
  • the recognition factor may be also a physical recognition moiety, such as a surface charge.
  • the charge may be introduced during the fabrication of the particle by using a chemical treatment such as a specific wash. For example, immersion of porous silica or oxidized silicon surface into water may lead to an acquisition of a negative charge on the surface, see, e.g., Behrens and Grier, J. Chem. Phys. 115(14), (2001). P. 6716-6761.
  • the surface charge may be also provided by an additional layer or by chemical chains, such as polymer chains, on the surface of the particle.
  • polyethylene glycol chains may be a source of a negative charge on the surface. Polyethylene glycol chains may be coated or covalently coupled to the surface as described in P. K.
  • the positive charge is introduced, for example, by coating the surface with a basic polymer, such as polylysine or by covalently linking to the surface an amino containing molecule, such as 3-aminopropyltriethoxysilane.
  • modeling methods are applied for selecting geometrical factors, such as a size and a shape, and/or surface modification, such as chemical modification and electrostatic modification, of the particle based on one or more properties of the selected target site.
  • geometrical factors such as a size and a shape, and/or surface modification, such as chemical modification and electrostatic modification, of the particle based on one or more properties of the selected target site.
  • Such modeling methods are disclosed, for example, in 1) U.S. Provisional Patent Application No. 60/829,075 “Particles for Cell Targeting” filed Oct. 11, 2006 to Paolo Decuzzi and Mauro Ferrari; 2) U.S. Provisional Patent Application No. 60/891,584 “Endocytotic particle” filed Feb. 26, 2007 to Paolo Decuzzi and Mauro Ferrari; 3) Decuzzi, P., Causa, F., Ferrari, M. & Netti, P. A.
  • the first stage particle is configured to release the second stage particles from its reservoir at the target site.
  • the release of the second stage particles may be performed according to a variety of mechanisms, including, but not limited to, diffusion of the second stage particles through the channels connecting the reservoir and the surface of the first stage particle and degradation or erosion of the body the first stage particle.
  • the first stage particle is configured to have a characteristic release time longer than a characteristic delivery time of the first stage particle to its target site when administered to the subject.
  • the first stage particle is configured to perform a release of the second stage particles from its reservoir that is sustained over a period of time longer than a characteristic delivery time of the first stage particle to its target site when administered to the subject. In some embodiments, the first stage particle is configured to release the second stage particles over a time period longer than at least 0.5 hr; or longer than at least 1 hr; or longer than at least 2 hr; or longer than at least 8 hr; or longer than at least 15 hr; or longer than 30 hr.
  • physical localization and/or targeted release of the first stage particle is initiated by one or more intrinsic physiological conditions at the target site such as pH, salt concentrations or temperature.
  • physical localization and/or targeted release of the first stage particle is initiated by exogenous stimulation.
  • exogenous stimulations include mechanical activation, such activation by ultrasound; electromagnetic activation, such an activation by visible, ultraviolet, near-infrared or infrared light, radiofrequency or X-ray radiation; magnetic radiation.
  • the first stage particle may comprise a smart polymer, i.e., a polymer that contracts or expand in a response to a specific stimulus, such as light, temperature or pH.
  • the first stage particle may utilize multiple, i.e., more than one recognition/localization/targeting factors, which preferably do not interfere with each other.
  • the first particle may have the selected non-spherical shape as discussed above and at the same time carry tumor-targeting antibodies on its surface.
  • the surface of the first stage particle may be coated with polymer chains partially or completely.
  • the polymer chains may be added after the fabrication of the intravascular stage particle.
  • the polymer chains may be hydrophilic chains, such as polyethylene glycol (PEG) chains or synthetic glycocalix chains, which may be used for overcoming the uptake of the particle by cell of the reticulo-endothelial system and, thus, extending the blood circulation of the intravascular stage particle.
  • the hydrophilic groups may also serve for enhancement of solubility of the multistage delivery devices.
  • a variety of materials may be derivatized with polymer chains.
  • polymer chains may be attached by linking carboxylic groups of the polymer and amine or hydroxyl groups in the polymer chains; if the particle's surface material comprises metal such as gold, the polymer chains may be attached to the surface via thiol chemistry; when the particle's surface material comprises an oxide, such silicon oxide, titanium oxide or aluminum oxide, the polymer chains may be attached using silane chemistry.
  • the reservoir of the first stage particle may contain one or more additional agents.
  • additional agent may include an additional active agent, such as a therapeutic agent or an imaging agent, a targeting agent, one or more penetration enhancers or any combination thereof.
  • the penetration enhancer may include one or more compounds listed in Table 1.
  • the penetration enhancers may include a basement membrane penetration enhancer that may act against the basement membrane, and/or one or more penetration enhancers, that may act against tight junction proteins (TJPs).
  • TJPs tight junction proteins
  • An example of the basement membrane penetration enhancer is metalloproteinase, such as Collagenase IV, MMP-2, and MMP-9.
  • An example of the anti-TJP penetration enhancer is zonula occluden toxin.
  • Anti-TJP penetration enhancers and strategies for modulating tight junction permeability are detailed, for example, in Gonzalez-Mariscal, L., Nava, P. and Hernandez, S. J. Membr. Biol., 2005. 207(2): p. 55-68.
  • FIGS. 2A-B illustrate the action of penetration enhancer upon localization of the first stage particle at the targeted vasculature site, in accordance with an embodiment.
  • the first stage particle releases the permeation enhancers that generate in the targeted vasculature one or more fenestrations, through which the second stage particles penetrate into the vasculature.
  • the first stage particle has one or more channels fluidically connecting the reservoir with the surface, that may be in contact with endo or epithelial cells.
  • such first stage particle may be a micro or nano fabricated particle, such as those detailed in U.S. Patent Application Publication No 2003/0114366 and U.S. Pat. No. 6,107,102, and for oral administration, such first stage particle may be a micro or fabricated particle, such as the ones disclosed in U.S. Pat. No. 6,355,270.
  • the reservoir and the channels are pores in the body of first stage particle.
  • the first stage particle may comprise a porous or nanoporous material.
  • the pores of the porous or nanoporous material may be controlled to achieve a desired load of the next stage particles and a desired release rate.
  • the nanoporous material with controllable pore size may be an oxide material, such as silicon oxide, aluminum oxide, titanium oxide, or iron oxide. Fabrication of nanoporous oxide particles, also known as sol gel particles, is detailed, for example, in Paik J. A. et. al. J. Mater. Res., Vol. 17, August 2002.
  • the nanoporous material with controllable pore size may be also nanoporous silicon.
  • Control of pore density, size, shape and/or orientation may be accomplished by changing electrical current and etching time during formation of nanoporous silicon from non-porous silicon. Control of pore density, size, shape and/or orientation may be also accomplished by varying doping in non-porous silicon used for formation of nanoporous silicon. Thus, pore size, density, size, shape and/or orientation of nanoporous may be configured for efficient loading of the second stage particles.
  • pore size in nanoporous first stage particles may be, for example, from about 1 nm to about 200 nm; or from about 2 nm to about 100 nm. In some cases, pore size in nanoporous first stage particle may be from about 3 to about 10 nm or from about 5 to about 7 nm. Yet in some cases, pore size in nanoporous first stage particle may be from about 10 to about 60 nm, or from about 20 to about 40 nm.
  • to facilitate loading of the second stage particles into pores of the porous or nanoporous material may be modified chemically and/or electrostatically to make it compatible with chemical and/or electrostatical surface properties of the second stage particles.
  • the positive charge may be achieved, for example, by depositing on pore surface an amino-containing molecule, such as 3-aminopropyltriethoxysilane.
  • For loading positively charged second stage particles it may be preferable to use negatively charged pore surface.
  • the negative pore surface charge may be accomplished, for example, by oxidizing pore surface with water.
  • the first stage particle has no channels at all.
  • Such particle may comprise, for example, a biodegradable material.
  • the material may be designed to erode in the GI tract.
  • the first stage particle may be formed of metals, such as iron, titanium, gold, silver, platinum, copper, and alloys and oxides thereof.
  • the biodegradable material may be also a biodegradable polymer, such as polyorthoesters, polyanhydrides, polyamides, polyalkylcyanoacrylates, polyphosphazenes, and polyesters. Exemplary biodegradable polymers are described, for example, in U.S. Pat. Nos. 4,933,185, 4,888,176, and 5,010,167.
  • biodegradable polymer materials include poly(lactic acid), polyglycolic acid, polycaprolactone, polyhydroxybutyrate, poly(N-palmitoyl-trans-4-hydroxy-L-proline ester) and poly(DTH carbonate).
  • the body of the first stage particle includes two or more regions configured to contain different populations of second stage particles.
  • the body of the first stage particle may have a first region configured to contain a first population of second stage particles and a second region configured to contain a second population of second stage particles.
  • the first stage particle formed of porous nanoporous material may be such that its body has two or more porous regions that differ from each other.
  • the body of the nanoporous first stage particle may include a first porous region and second porous region that differ from each other in at least one property such as a pore density, pore geometry; pore charge, pore surface chemistry, pore orientation or any combination thereof.
  • Such first and second regions may be configured respectively to contain a first and a second population of second stage particles.
  • the first and second populations of second stage particles differ in at least one property such as size; shape; surface chemical modification; surface charge or a combination thereof.
  • the first and second populations of second stage particles contain the same active agent. Yet, in some embodiments, the first and second population of second stage particles contain respectively a first active agent and a second active agent that are different from each other.
  • the first and second populations of second stage particles may be configured to perform different functions.
  • the first and second populations may be configured to target respectively a first and second target sites that are different from each other.
  • the first population are configured to target a particular site in a body of the subject, while the second population is configured to free circulate in the blood system of the subject.
  • the first and the second population target the same target site in a body of the subject but perform a different function at the body site.
  • the first population contains a therapeutic agent to be delivered to the target site
  • the second population contains an imaging agent to be delivered to the target site for imaging or visualizing the target site.
  • the first and the second regions of the body of the first stage particle may be such that at least one of them is a biodegradable region.
  • both the first and the second regions of the body of the first stage particle is biodegradable.
  • the first and the second regions of the body of the first stage particle may have different characteristic time for releasing the first and the second population of second stage particles.
  • both characteristic time for releasing the first population of second stage particles from the first region and characteristic time for releasing the second population of second stage particles from the second region may be greater that a characteristic for delivery and/or localization of the first stage particle at its target site when administered to the subject.
  • the first stage particle is configured to separate into a first component that includes the first region and a second component that includes the second region when being exposed to a physiological medium, such as a medium that may be present at a target site of the first stage particle. Such exposure may occur, for example, when the particle is administered to the subject.
  • the first and the second regions of the body of the first stage particle are configured to perform a different function when the particle is administered to the subject.
  • the first and the second region of the body of the first stage particle may be configured to overcome respectively the first and the second biological barriers that are different from each other.
  • Such biological barriers may be each selected, for example, from a hemo-rheology barrier, a Reticulo-Endothelial System barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier or a combination thereof.
  • the second stage particle may be any micro or nanoparticle that may fit inside the reservoir of the first stage particle.
  • the second stage particle is the same as the first stage particle for intravascular administration.
  • the particle of the second stage may be configured to overcome at least one barrier selected from a hemo-rheology barrier, a Reticulo-Endothelial System barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier or a combination thereof.
  • a hemo-rheology barrier a Reticulo-Endothelial System barrier
  • an endothelial barrier a blood brain barrier
  • a tumor-associated osmotic interstitial pressure barrier an ionic and molecular pump barrier
  • a cell membrane barrier an enzymatic degradation barrier
  • nuclear membrane barrier or a combination thereof.
  • the second stage particle may be a lipid based particle, such as a liposome, a micelle or lipid encapsulated perfluorocarbon emulsion; an ethosome; a carbon nanotube, such as single wall carbon nanotube; a fullerene nanoparticle; a metal nanoparticle, such gold nanoshell or triangular silver nanoparticle; a semiconductor nanoparticle, such as quantum dot or boron doped silicon nanowire; a polymer nanoparticle, such as particles made of biodegradable polymers and ion doped polyacrylamide particles; an oxide nanoparticle, such as iron oxide particle, a polymer coated iron oxide nanoparticle or a silicon oxide particle; a viral particle, such as an engineered viral particle or an engineered virus-polymer particle; a polyionic particle, such as leashed polycations; a ceramic particle, such as silica based ceramic nanoparticles, or
  • the second stage particle is configured to target a particular target site in a body of the subject.
  • target site may be the same or different from the target site targeted by the first stage particle.
  • the surface of the second stage particle may have one or more antibodies that may conjugate with surface marker antigens of certain types of cells.
  • the second stage particle may selectively target cells that carry such marker antigens.
  • the examples of cells that carry surface marker antigens include stem or clonogenic cells and tumor cells.
  • the surface marker antigens on stem or clonogenic cells may be targeted by CD33 antibody.
  • a number of monoclonal antibodies to tumor specific antigens are available, see, e.g., pp. 301-323 of CANCER, 3rd Ed., De Vita, et. al. eds; Janeway et. al. Immunology 5th Edition, Garland Press, New York, 2001; A. N. Nagappa, D. Mukherjee & K. Anusha “Therapeutic Monoclonal Antibodies”, PharmaBiz.com, Wednesday, Sep. 22, 2004. Table 2 presents FDA approved monoclonal antibodies for treatment of cancer.
  • the second stage particle is configured to freely circulate in a blood system of the subject upon being released from the first stage particle.
  • such second stage particle may have a surface free of targeting moieties, such as antibodies.
  • the free circulating second stage particle may be used, for example, as to report of therapeutic action a therapeutic agent associated with a first stage particle per se.
  • the surface of the second stage particle does not have hydrophilic polymer chains, such as polyethylene glycol (PEG) disposed on it.
  • PEG polyethylene glycol
  • this may be an advantage of the multistage delivery vehicle as PEG chains are usually attached to liposomes and other nanoparticles to delay recognition and sequestration by macrophages of the reticulo-endothelial system.
  • the PEG chains may also hide antibodies on the nanoparticles surfaces and thus inhibit the targeting/localization ability of the antibodies.
  • PEGs attached to the first stage particle may perform shielding from the RES macrophages.
  • the recognition/localization capability of the first stage particle is not limited to the antibodies, as other factors such as the particle's size and shape also may contribute to such capability.
  • the surface of the second stage particle has hydrophilic polymer chains, such as PEG chains, disposed on it.
  • the surface of second stage particle is modified, for example, to facilitate the second stage particle's ability to load into a reservoir of the first stage particle and/or to facilitate the second stage particle's ability to reach its target site.
  • the surface modification may include a chemical modification of the surface of the second stage particle and/or electrostatic modification of the surface of the second stage particle.
  • the surface of the second stage particles may be modified so that its properties are compatible with surface properties of pores of the porous or nanoporous first stage particle.
  • the pores of the porous or nanoporous first stage particle when the pores of the porous or nanoporous first stage particle are positively charged it may be preferably to modify the surface of the second stage particles so that they are electrostatically neutral or have a negative surface charge; while when the pores of the porous or nanoporous first stage particle are negatively charged, it may be preferably to modify the surface of the second stage particles so that they are electrostatically neutral or have a positive surface charge.
  • the chemical and/or electrostatic surface modification of the second stage particles may be performed using the same methods as detailed above to the first stage particles.
  • the electrostatic modification may be performed by incorporating in their lipid layers lipids that may affect the electrostatic charge of the liposome.
  • lipids that may affect the electrostatic charge of the liposome.
  • cationic lipids such as 1,2-Dioleyl-3-trymethylammoniumpropane (DOTAP)
  • DOTAP 1,2-Dioleyl-3-trymethylammoniumpropane
  • anionic lipids such as dioleoylphosphatidyl glycerol (DOPG)
  • DOPG dioleoylphosphatidyl glycerol
  • DOPC dioleoylphosphatidyl glycerol
  • the second stage particle may release its content into the cell's cytoplasm.
  • such release is activated by exogenous factors, such as electromagnetic radiation.
  • exogenous factors such as electromagnetic radiation.
  • such radiation may be radio-frequency radiation
  • gold-shell nanoparticles the radiation may be a near-infrared radiation.
  • Activation of nanoparticulates by exogenous radiation is detailed, for example, Hirsch, L. R., Halas, N. J. & West, J. L. Anal. Chem. 75, 2377-2381 (2003); Hirsch, L. R., Halas, N. J. & West, J. L. Proc. Natl. Acad. Sci. USA 100, 13549-13554 (2003); and O'Neal, D. P., Halas, N. J. & West, J. L. Cancer Lett. 209, 171-176 (2004).
  • the content of the second stage particle is one or more active agents per se.
  • the second stage particle contains inside a third stage particle, which itself contains inside one or more active agents.
  • the third stage particle may be, for example, a particle, that is small enough to be able to cross a nuclear membrane of the targeted cell.
  • the third stage particle may serve for delivering to the cell's nucleus an active agent, that may be an agent acting against nucleic acids or a gene therapeutic agent.
  • the third stage particle may range from about 3 nm to about 10 nm.
  • the ability to deliver nanoparticles in 3 nm to 10 nm size range may be one of the advantages of the multistage delivery vehicle as a conventional administration of such particles via injection usually results in their immediate globular clearance.
  • the multistage vehicle includes a third stage.
  • the third stage may be any nanoparticle that may fit inside the second stage particle.
  • the third stage particle may be a lipid based particle, such as a liposome, a micelle or lipid encapsulated perfluorocarbon emulsion; an ethosome; a carbon nanotube, such as single wall carbon nanotube; a fullerene nanoparticle; a metal nanoparticle, such gold nanoshell or triangular silver nanoparticle; a semiconductor nanoparticle, such as quantum dot or boron doped silicon nanowire; a polymer nanoparticle, such as particles made of biodegradable polymers and ion doped polyacrylamide particles; an oxide nanoparticle, such as iron oxide particle, a polymer coated iron oxide nanoparticle or a silicon oxide particle; a viral particle, such as an engineered viral particle or an engineered virus-polymer particle; a polyionic particle, such as leashed polycations; a ceramic
  • Later stage particles may be introduced into a earlier stage particle of an earlier stage by any appropriate technique.
  • one may soak nanoporous earlier stage particles fabricated in a solution containing a carrying fluid and the later stage particles, which may enter pores of the earlier stage particle via capillary action and/or diffusion.
  • the carrying fluid may be a liquid that is biologically non-harmful and that is neutral with respect to the earlier stage particle's material.
  • An example of the carrying fluid may be phosphate buffer saline (PBS) or a deionized water.
  • the solution may also contain one or more additional agents, such one or more additional therapeutic agents and one or more appropriate penetration enhancers, desired to be introduced in the first stage particle.
  • To maximize a load of the later stage particles one may use a solution that has a saturated concentration of the later stage particles.
  • the earlier stage particles may be introduced into the solution in a form of suspension.
  • Preparation of Nanoporous Particles Suspension is Detailed, for Example, in U.S. Patent Application No. 2003/0114366. Pores of the nanoporous particles may be dried prior their submerging in the solution containing the later stage particles.
  • the solution containing the later stage particles pores may be degassed prior to the introduction of the earlier stage particles. Then, the earlier stage particles may be submerged in the degassed solution in a sealed chamber. The earlier stage particles may be subjected to reduced pressure to ensure that trapped air is forced from the pores in the particles. Then the earlier stage particles may be fully immersed in the solution and the pressure in the sealed chamber may be elevated slightly above atmospheric to make sure that the solution enters the pores of the earlier stage particles. The earlier stage particles may then be trapped on a filter and dried using one of the three methods described below.
  • the pressure within the chamber is reduced and then raised slightly above atmospheric pressure.
  • drying is achieved by one or more of the following three methods.
  • Water may be removed by evaporation under reduced pressure in a vacuum chamber, or by passage of a stream of warm air or an inert gas such as nitrogen over the surface particles collected on a filter, or by freeze drying.
  • a flat heat exchanger may be placed in good thermal contact, e.g. directly below, the filter, on which the earlier stage particles have been collected.
  • Refrigerant fluid at temperatures ranging from ⁇ 20° C. to ⁇ 60° C., such as Freon, or a cold liquid, such as liquid nitrogen, may be passed through the heat exchanger flowing into port and passing out port in order to freeze any water remaining within the pores. The pressure may be then reduced until all the water sublimes.
  • a solution containing the earlier stage nanoporous particles, the later stage particles and a carrier liquid is prepared.
  • the carrier liquid may be a physiological buffer, such as Tris-HCl.
  • a concentration of the carrier liquid may be selected by using standard techniques to maximize loading of the later stage particle into the nanoporous earlier stage particles. For example, in some embodiments, for Tris-HCl, the optimal concentration may be selected from 1 to 500 mM.
  • Geometrical properties of the later stage particles may be selected to be compatible pore properties of the nanoporous earlier stage particles, such as pore density, pore size, and pore orientation.
  • loading of the later stage particle into the nanoporous earlier stage particles is facilitated by agitating the solution containing both the later stage and earlier stage particles.
  • Such agitation may be performed by spinning the solution in a rotating wheel.
  • Agitation conditions, such as a rotation speed of the rotating wheel, may be optimized using standard techniques to achieve a desired loading degree and/or loading time.
  • loading of the later stage particles into the earlier stage nanoporous particles is controlled by varying a concentration of the later stage particles in the solution.
  • the higher load may be achieved by using a higher concentration of the later stage particles in the solution.
  • one may achieve a higher load of the later stage particles by using a concentration of the later stage particles, which is lower than the highest possible concentration of the later stage particles in the solution. Determining a concentration maximizing loading of the later stage particles in the nanoporous earlier stage particles may be performed using standard methods.
  • loading of the later stage particles into the earlier stage nanoporous particles is controlled by modifying a pore surface of the nanoporous earlier stage particles and/or a surface of the later stage particles in order to make them more compatible.
  • Such modifying may be performed by modifying surface chemical groups on either surface and/or by modifying an electrical charge on either surface.
  • to achieve a higher load of the later stage particle one may use negatively charged surface of the later stage particles and positively charged porous surface of the earlier stage nanoporous particles or positively charged surface of the later stage particles and negatively charged porous surface of the earlier stage nanoporous particles.
  • a pore surface of the nanoporous earlier stage particles and a surface of the later stage particles are modified with chemical groups compatible with each other.
  • one of the pore surface of the nanoporous earlier stage particles and the surface of the later stage particles may be modified with carboxy groups; while the other may be modified with amino groups.
  • the active agent may be a therapeutic agent, an imaging agent or a combination thereof.
  • the active agent may be any appropriate agent that may be released from a particle containing it. The selection of the active agent depends on the application.
  • the active agent When the active agent is not a particle of any stage per se, it may be introduced into particle using any appropriate technique.
  • the active agent when the active agent is doxorubicin, it may be introduced in a liposome particle using a protocol detailed in Working Example 4.
  • the active agent when the active agent is a particle of one of the stages of multistage delivery vehicle, the active agent may introduced using one of the methods disclosed above.
  • the therapeutic agent may be any physiologically or pharmacologically active substance that may produce a desired biological effect in a targeted site in an animal, such as a mammal or a human.
  • the therapeutic agent may be any inorganic or organic compound, without limitation, including peptides, proteins, nucleic acids, and small molecules, any of which may be characterized or uncharacterized.
  • the therapeutic agent may be in various forms, such as an unchanged molecules, molecular complex, pharmacologically acceptable salt, such as hydrochloride, hydrobromide, sulfate, laurate, palmitate, phosphate, nitrite, nitrate, borate, acetate, maleate, tartrate, oleate, salicylate, and the like.
  • salts of metals, amines or organic cations for example, quaternary ammonium
  • derivatives of drugs such as bases, esters and amides also may be used as a therapeutic agent.
  • a therapeutic agent that is water insoluble may be used in a form that is a water soluble derivative thereof, or as a base derivative thereof, which in either instance, or by its delivery, is converted by enzymes, hydrolyzed by the body pH, or by other metabolic processes to the original therapeutically active form.
  • the therapeutic agent may be a chemotherapeutic agent, an immunosuppressive agent, a cytokine, a cytotoxic agent, a nucleolytic compound, a radioactive isotope, a receptor, and a pro-drug activating enzyme, which may be naturally occurring or produced by synthetic or recombinant methods, or any combination thereof.
  • Drugs that are affected by classical multidrug resistance such as vinca alkaloids (e.g., vinblastine and vincristine), the anthracyclines (e.g., doxorubicin and daunorubicin), RNA transcription inhibitors (e.g., actinomycin-D) and microtubule stabilizing drugs (e.g., paclitaxel) may have particular utility as the therapeutic agent.
  • vinca alkaloids e.g., vinblastine and vincristine
  • anthracyclines e.g., doxorubicin and daunorubicin
  • RNA transcription inhibitors e.g., actinomycin-D
  • microtubule stabilizing drugs e.g., paclitaxel
  • a cancer chemotherapy agents may be a preferred therapeutic agent.
  • Useful cancer chemotherapy drugs include nitrogen mustards, nitrosorueas, ethyleneimine, alkane sulfonates, tetrazine, platinum compounds, pyrimidine analogs, purine analogs, antimetabolites, folate analogs, anthracyclines, taxanes, vinca alkaloids, topoisomerase inhibitors and hormonal agents.
  • Exemplary chemotherapy drugs are Actinomycin-D, Alkeran, Ara-C, Anastrozole, Asparaginase, BiCNU, Bicalutamide, Bleomycin, Busulfan, Capecitabine, Carboplatin, Carboplatinum, Carmustine, CCNU, Chlorambucil, Cisplatin, Cladribine, CPT-11, Cyclophosphamide, Cytarabine, Cytosine arabinoside, Cytoxan, dacarbazine, Dactinomycin, Daunorubicin, Dexrazoxane, Docetaxel, Doxorubicin, DTIC, Epirubicin, Ethyleneimine, Etoposide, Floxuridine, Fludarabine, Fluorouracil, Flutamide, Fotemustine, Gemcitabine, Herceptin, Hexamethylamine, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Mechloreth
  • Useful cancer chemotherapy drugs also include alkylating agents, such as Thiotepa and cyclosphosphamide; alkyl sulfonates such as Busulfan, Improsulfan and Piposulfan; aziridines such as Benzodopa, Carboquone, Meturedopa, and Uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as Chlorambucil, Chlomaphazine, Cholophosphamide, Estramustine, Ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, Melphalan, Novembiehin, Phenesterine, Prednimustine, Trofosfamide, uracil mustard; nitroureas such as Cannustine, Chlorozotocin, Fotem
  • anti-hormonal agents that act to regulate or inhibit hormone action on tumors
  • anti-estrogens including for example Tamoxifen, Raloxifene, aromatase inhibiting 4(5)-imidazoles, 4 Hydroxytamoxifen, Trioxifene, Keoxifene, Onapristone, And Toremifene (Fareston); and anti-androgens such as Flutamide, Nilutamide, Bicalutamide, Leuprolide, and Goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
  • Cytokines may be also used as the therapeutic agent.
  • cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor- ⁇ and - ⁇ ; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- ⁇ ; platelet growth factor; transforming growth factors (TGFs) such as TGF- ⁇ and T
  • the imaging agent may be any substance that provides imaging information about a targeted site in a body of an animal, such as a mammal or a human being.
  • the imaging agent may comprise magnetic material, such as iron oxide, for magnetic resonance imaging.
  • the active agent may be, for example, semiconductor nanocrystal or quantum dot.
  • the imaging agent may be metal, e.g., gold or silver, nanocage particles.
  • the imaging agent may be also an ultrasound contrast agent, such as a micro or nanobubble or iron oxide micro or nanoparticle.
  • the multistage delivery vehicle may be administered as a part of a composition, that includes a plurality of the vehicles, to a subject, such as human, via any suitable administration method in order to treat, prevent and/or monitor a physiological condition, such as a disease.
  • a composition may be administered by one of the following routes: topical, parenteral, inhalation/pulmonary, oral, vaginal and anal.
  • Embodiments of the multistage delivery vehicles may be particularly useful for oncological applications, i.e. for treatment and/or monitoring cancer or a condition, such as tumor associated with cancer.
  • skin cancer may be treated and/or monitored by topical application of, preferably, a viscous suspension
  • lung cancer may be treated and/or monitored by inhalation of an aerosolized aqueous microdevice suspension
  • cervical cancer may be treated and/or monitored by vaginal administration of a microdevice suspension
  • colon cancer may be treated and/or monitored by rectal administration of such a suspension.
  • the majority of therapeutic applications may involve some type of parenteral administration, which includes intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) injection.
  • Administration of the multistage delivery vehicles may be systemic or local.
  • the non-parenteral examples of administration recited above, as well as i.m. and s.c. injections, are examples of local administration.
  • Intravascular administration may be either local or systemic.
  • Local intravascular delivery may be used to bring a therapeutic substance to the vicinity of a known lesion by use of guided catheter system, such as a CAT-scan guided catheter.
  • General injection such as a bolus i.v. injection or continuous/trickle-feed i.v. infusion are typically systemic.
  • the multistage delivery vehicle may be formulated as a suspension that contains a plurality of the vehicles.
  • the vehicles are uniform in their dimensions and their content.
  • the vehicles as described above may be suspended in any suitable aqueous carrier vehicle.
  • a suitable pharmaceutical carrier is one that is non-toxic to the recipient at the dosages and concentrations employed and is compatible with other ingredients in the formulation. Preparation of suspension of microfabricated particles is disclosed, for example, in US patent application publication No. 20030114366.
  • the multistage delivery vehicle may administered as a part of an oral composition made up of a plurality of the vehicles.
  • the vehicles in the composition are uniform in dimensions, i.e. the first stage particles of each vehicle have the same or substantially the same dimension; the second stage particles of each vehicle have the same or substantially the same dimensions.
  • the composition may be made by mixing the vehicles with suitable non-aqueous carriers, such as oil or micronized powder, and filled in unit dose amounts into standard enteric-coated capsules or, alternatively, compressed into tablets and coated with an enteric coating material.
  • suitable non-aqueous carriers such as oil or micronized powder
  • the composition may be coated with a protective polymer.
  • This material may be applied by film coating technology to either tablets or capsules to protect the product from the effects of, or prevent release of drugs in, the gastric environment.
  • Such coatings are those, which remain intact in the stomach, but may dissolve and release the contents of the dosage form once it reaches the small intestine.
  • the purpose of an enteric coating may be to delay release of the first stage particle's content.
  • enteric polymer may be cellulose acetate phthalate (CAP).
  • CAP cellulose acetate phthalate
  • PVAP polyvinyl acetate phthalate
  • Another useful polymer may be polyvinyl acetate phthalate (PVAP), which is less permeable to moisture, more stable to hydrolysis and able to ionize at a lower pH than is CAP. These properties may allow more reliable release in the duodenum.
  • PVAP polyvinyl acetate phthalate
  • Another example of currently used polymers may be those based on methacrylic acid-methacrylic acid ester copolymers with acid ionizable groups. Represented among these are polymers having the tradename Eudragit available through Rohm Pharma.
  • the enteric coating may be applied from about 0.5% by weight to about 10% by weight of the tablet or capsule.
  • a less water-soluble polymer such as methylcellulose
  • ChronSet® technology developed by ALZA Corporation may be used to release a bolus of the multistage delivery vehicles at designated times and at targeted sites after passage from the stomach into the small intestine.
  • a suspension of the vehicles may be loaded into ChronSet capsules. After swallowing, the capsules pass intact through the stomach.
  • the shell may be engineered to regulate the rate of water imbibition the osmotically permeable portion of the system.
  • the osmotic engine may expand to push and separate two halves of the capsule.
  • the length of the capsule halves may be specifically designed to produce separation at pre-selected times.
  • the contents of each capsule may be expelled into the intestinal lumen at 2 to 20 hours after administration. Greater than 80% of contents (in this case a suspension of drug-filled microfabricated particles) may be expelled within 15 minutes time frame. This approach may provide a means of releasing the suspension of the vehicles at preselected areas of the small or large intestine.
  • Such a system may be used to release the multistage delivery vehicles at sites in the small or large intestine that are optimal for binding, such as areas, which contain receptors for the muco-adhesive ligand grafted to the particles, and/or absorption, such as regions of the intestinal epithelium that are sensitive to the permeation enhancers contained inside the first stage particle.
  • Particles were counted in a Z2 Coulter® Particle Counter and Size Analyzer (Beckman Coulter).
  • the aperture size used for particle analysis was 50 ⁇ m.
  • the lower and upper size limits for analysis were set at 1.8 and 3.6 ⁇ m.
  • particles were suspended in the balanced electrolyte solution of the instrument (ISOTON® II Diluent) and counted. The total volume of original suspension of particles did not exceed 0.3% of the final analysis volume.
  • Silicon microparticles in IPA were dried in a glass beaker kept on a hot plate (80-90° C.). Silicon particles were oxidized in piranha (1 volume H 2 O 2 and 2 volumes of H 2 SO 4 ). The particles sonicated after H 2 O 2 addition and then acid was added. The suspension was heated to 100-110° C. for 2 hours with intermittent sonication to disperse the particles. The suspension was then washed in DI water till the pH of the suspension is 5.5-6. Particles were then transferred to appropriate buffer, IPA or stored in water and refrigerated till further use.
  • the oxidized particles Prior to the silanization process, the oxidized particles were hydroxylated in 1.5 M HNO 3 acid for approximately 1.5 hours (room temperature). Particles were washed 3-5 times in DI water (washing includes suspending in water and centrifuging, followed by the removal of supernatant and the repeating of the procedure).
  • the particles were suspended in IPA (isopropyl alcohol) by washing them in IPA twice. They were then suspended in IPA containing 0.5% (v/v) of APTES (3-aminopropyltriethoxysilane) for 45 minutes at room temperature. The particles were then washed with IPA 4-6 times by centrifugation and stored in IPA refrigerated. Alternatively, they were aliquoted, dried and stored under vacuum and dessicant till further use.
  • IPA isopropyl alcohol
  • PEG was attached to the microparticles to provide a spacer for further coupling with anti-VEGFR2 antibody.
  • Fmoc-PEG-NHS which provided the NHS ester for rapid coupling to amine groups and an Fmoc group to protect the amine on the PEG, was used.
  • the 106-109 particles/ml of APTES modified microparticles were resuspended in PBS (pH7.2) and Fmoc-PEG-NHS at a concentration of 1-10 mM added to the particles.
  • the antibody to VEGFR2 was conjugated with Alexa 488 using an antibody labeling kit from Invitrogen Corp.
  • the fluorescent tag was conjugated to the antibody by following the procedure provided in the manual of the kit. 1 mg/ml of antibody was used for tagging. The amount of antibody conjugated to the fluorescent tag was determined by analyzing the antibody with a DU® 730 UV/Vis Spectrophotometer (Beckman Coulter Inc., CA, USA) at 280 and 494 nm. The amount of antibody conjugated was found to be 407 ⁇ g/ml.
  • the different amounts of antibody used were 0.814, 0.407, and 0.163 ⁇ g, corresponding to 2.7, 1.35, and 0.54 ⁇ g/ml respectively, and exposed to UV light for 10-15 min to couple the amine groups present on the antibody to the attached crosslinker.
  • FIG. 3 Panel A, presents results of time dynamics for loading carboxy modified quantum dots and amino modified quantum dots into APTES modified LP and SP silicon particles.
  • FIG. 4 Panels A-D present results of time dynamics for loading carboxy modified quantum dots and amino modified dots into (Panel A) LP oxidized silicon particles; (Panel B) LP APTES modified silicon particles; (Panel C) SP oxidized silicon particles and (Panel D) SP APTES modified silicon particles.
  • Each of Panels A-D also presents time dynamics for loading PEG-FITC single wall carbon nanotubes, as described below.
  • 1.2 ⁇ 10 6 LP and SP oxidized silicon or APTES modified microparticles were combined with 2 ⁇ M Amino-PEG Q-dots or Carboxyl Q-dots in 200 mM TRIS-HCl pH 7.3 in a 80 ⁇ l final volume. Particles and Q-dots were incubated in a rotating wheel (20 rpm) and sampled out from the vial after 15, 30, 45 and 60 minutes at 25° C. After incubation, the samples were diluted with Tris 20 mM, pH 7.3 to 150 ⁇ l and promptly read at a FACScalibur flow cytometer for fluorescence intensity.
  • 2.1 ⁇ 10 6 LP silicon microparticles either oxidized or APTES modified were combined with 2 ⁇ M Amino-PEG Q-dots or Carboxyl Q-dots respectively, in a TRIS-HCl 200 mM pH7.3 solution. Final incubation volume was 140 ⁇ l. Samples were incubated in a rotating wheel (20 rpm) for 15 minutes at 25° C. The microparticles were then washed in 1.4 mL deionized water (10 folds dilution), and centrifuged 5 minutes at 4200 RPM in a Beckman Coulter Allegra X-22 centrifuge.
  • Particles pellet was resuspended in 70 ⁇ l of deionized water and 10 ⁇ l were taken out the vial, diluted with a TRIS 20 mM, pH 7.3 solution to 150 ⁇ l final volume. Sample's fluorescence was immediately read with Becton Dickinson FACScalibur flow cytometer and recorded as time 0 or loading fluorescence.
  • the residual 60 ⁇ l were diluted 10 times into 600 ⁇ L of TRIS-HCL 20 mM NaCl 0.9% release buffer. 100 ⁇ l were taken out this solution and additionally diluted 5 times by aliquoting the sample into tubes pre filled with 400 uL TRIS-HCL 20 mM NaCl 0.9% release buffer. Final dilution at this point was 500 folds. Samples were put in a rotating wheel (20 rpm) for the given amount of time (15, 45, 90, 180, 360 and 1200 minutes) minutes at 37° C. At each time point the aliquots were centrifuged 5 minutes at 4200 RPM in a Beckman Coulter Allegra X-22 centrifuge.
  • FIG. 5A presents time dynamics of release of amino-modified quantum dots from LP oxidized silicon particles.
  • FIG. 5B presents time dynamics of release of carboxy modified quantum dots from APTES modified LP silicon particles.
  • a concentration curve for PEG-FITC SWNTs in 20 mM TRIS-HCL pH 7.3 was determined using a SPECTRAmax fluorimeter. A serial dilution was performed, starting with 35 ng/ ⁇ l and proceeding by a factor of 1:2 down to minimum detectable amount of 107 pg/ ⁇ l. The aliquots were placed in a 96 well plate and the fluorescence was read using excitation at 485, and emission at 520. Fluorescence quenching was observed at the higher concentrations of SWNTs, as shown by their lower fluorescence.
  • Particles pellet was re-suspended in 60 ⁇ l of deionized water and 10 ⁇ l were taken out the vial, diluted with a TRIS 20 mM, pH 7.3 solution to 150 ⁇ l final volume. Sample's fluorescence was immediately read with Becton Dickinson FACScalibur flow cytometer and recorded as time 0 or loading fluorescence.
  • the residual 50 ⁇ l were diluted 10 times into 500 ⁇ L of TRIS-HCL 20 mM NaCl 0.9% release buffer. 100 ⁇ l were taken out this solution and additionally diluted 5 times by aliquoting the sample into tubes pre filled with 400 uL TRIS-HCL 20 mM NaCl 0.9% release buffer. Final dilution at this point was 500 folds. Samples were put in a rotating wheel (20 rpm) for the given amount of time (15, 45, 120, 240 and 1200 minutes) minutes at 37° C. At each time point the aliquots were centrifuged 5 minutes at 4200 RPM in a Beckman Coulter Allegra X-22 centrifuge.
  • FIG. 5A presents time dynamics of release of PEG-FITC-SWNTs from LP oxidized silicon particles.
  • FIG. 5B presents time dynamics of release of PEG-FITC-SWNTs from APTES modified LP silicon particles.
  • LP and SP oxidized silicon microparticles were combined with 10 ng/ ⁇ l of liposomes, containing an Alexa fluo 555 conjugated siRNA, in a 20 mM TRIS-HCl pH7.3 solution.
  • Particles and nanoliposomes were incubated in a rotating wheel (20 rpm) and sampled out from the vial after 15, 30 and 60 minutes at 25° C. After incubation, the samples were diluted with Tris 20 mM, pH 7.3 to 150 ⁇ l and promptly read at a FACScalibur flow cytometer for fluorescence intensity.
  • 5 ⁇ 10 6 LP and SP oxidized silicon particles were either mixed in a solution containing 2.5 mM TRIS and 0.9% NaCl at pH 7.3 (Saline) or in cell culture media supplemented with 10% FBS (CCM). The mixture was incubated in a rotating wheel (8 rpm) at 37° C. and sampling for SEM, Z2 and ICP was performed at time 0 and after 6, 18 and 24 hours.
  • the experiment was designed in order to have enough material to perform the three types of analysis for the degradation study in parallel at the same time, thus avoiding differences due to uncontrolled or unnoticed variables. This protocol therefore applied to the samples obtained for SEM, Z2 and ICP.
  • porous Silicon particles disappeared from the solutions, they were incubated in, the porous Silicon particles were dissolved in Silicic Acid and studied by a technique called Inductive Coupled Plasma Atomic Emission Spectrometry (ICP-AES).
  • ICP-AES Inductive Coupled Plasma Atomic Emission Spectrometry
  • FCS foetal calf serum
  • FCS foetal calf serum
  • EGF epidermal growth factor
  • -ECGF endothelial cell growth factor
  • the plates were incubated at 37° C. and, at the time points of 12, 24, 48 and 72 hours, the toxicity assay was performed as described for the calibration assay with the exception of Triton addition. All the experiments were done in triplicate and results expressed as mean values with standard deviations.
  • the plates were incubated at 37° C. and, at the time points of 12, 24, 48 and 72 hours, the medium was removed from the well and the cells extensively washed with sterile PBS to remove Silicon particles.
  • the proliferation assay was then performed as described for the calibration assay. All the experiments were done in triplicate and results expressed as mean values with standard deviations.
  • 0.6 ⁇ 10 6 cells were seeded in 25 cm 2 flasks and when the cells were attached (approximately 6 hours later, when the cells generated a 60% confluent cell bed), 3 ⁇ 10 6 of either LP oxidized, SP oxidized, LP APTES or SP APTES Silicon particles (1:5 ratio) resuspended in 20 ⁇ l of sterile, deionized H 2 O, were added to the medium of each flask.
  • deionized H 2 O were added to the cells while as a negative control we added 50 ⁇ g/ml of Cis-platinum to cell culture media.
  • the same amount of HUVEC cells was seeded in 75 cm 2 flasks to allow them to freely grow without reaching confluency during the experiment.
  • a solution containing (50 ⁇ g/ml propidium iodide in 10 mM Tris, 5 mM MgCl 2 , pH 7.3 and 75 ⁇ g/ml RNAse) was then added to the cell pellet and the suspension was incubated in dark on a rotating wheel (5 rpm) for 60 minutes. Samples were then transferred into FACS tubes and immediately read with a Becton Dickinson flow cytometer.
  • a polygonal region (R1) was defined around the centre of the population excluding the events that were to close to the noise signal of the instrument. For each sample, the number of particles detected in the R1 region was above 80%.
  • MFI mean fluorescence intensity
  • detectors used were forward scatter (FSC) E-1 and side scatter (SSC) with 474V voltage set.
  • the fluorescent detector FL1 was set at 800V.
  • Green fluorescence (FITC and Q-dots 525) was detected using FL1, 530/30 nm band-pass filter. Orange and red fluorescence (Q-dots D565 and Propidium Iodide) was detected using FL2. As single color detection only was being analyzed compensation was set at zero. Instrument calibration was carried out before, in between and after each series of acquisition using rainbow BD CalibriteTM beads.
  • detectors used were linear forward scatter (FSC) E00 with an amplification gain of 4.59 and linear side scatter (SSC) with the voltage set at 474V with an amplification gain of 1.07.
  • the fluorescent detectors FL2 was set at 449V with the amplification gain set at 1.32.
  • Fluorescent imaging of particles was performed with a Nikon Eclipse TE2000-E with a DQC-FS Nikon CCD Camera kept at ⁇ 30.1° C. All the samples were mounted immediately before the analysis and the images acquired with a 63 ⁇ immersion oil objective. The microscope settings were kept constant throughout all the experiments. Numerical Aperture was set at 1.4, Refractive Index at 1.515, Exposure Time at 500 ms, Readout Speed at 10 MHz and Conversion Gain at 1 ⁇ 6 ⁇ . The images were analyzed and measured with the NIS Elements AR 2.3 Software.
  • the total number of particles used for conjugating APTES modified particles with the anti-VEGFR2 was ⁇ 7.03 ⁇ 10 6 .
  • Two different amounts of anti-VEGFR2 were used for the conjugation as listed in Table 3 below.
  • Anti-VEGFR2 per Particles Amt. of Anti-VEGFR2 10 6 particles ID No. of particles ( ⁇ g) ( ⁇ g) APTES 1 7.42 ⁇ 10 5 0.065 0.088 APTES 2 7.42 ⁇ 10 5 0.022 0.03
  • Qdots Quantum dots
  • SWNT single-wall carbon nanotubes
  • Q-dots are light-emitting semiconductor nanocrystal (CdSe or CdTe), and many research has been conducted on in-vitro and in-vivo molecular and cellular imaging because of their high brightness, photostability and the capacity of multiplexed color coding.
  • Q-dots were coated with hydrophilic polyethylene glycol (PEG) to increase biocompability.
  • the zeta potential was ⁇ 1 mV for Amino-PEG Qdots in 20 mM Trs buffer, and ⁇ 32.8 mV for carboxyl PEG Q-dots.
  • the hydrodynamic size was measured by the diffusion coefficient of colloidals in solution using scattering light dynamic light scattering technique. Amino and Carboxyl Q-dots show similar hydrodynamics size (13 and 17 nm respectively).
  • SWNT is well-ordered hollow “rolled-up” structures, and has high aspect ratio, high surface area, high mechanical strength, ultra light weight, excellent chemical/thermal stability.
  • Many protocols have been studied to functionalize the SWNT surface with peptides, proteins and drugs.
  • SWNT was of diameter 2-4 nm and lengths between 30 and 100 nm, the surface was functionalized with PEG-amine, providing solubility in water and physiological saline and further linked to FITC for fluorescent imaging.
  • the zeta potential measurement shows ⁇ 9.2 mV in 20 nM TRIS buffer.
  • Tris concentration was selected as a buffering agent because, it may give the highest stability to the quantum dots (Q-dots) compared to other buffering agents.
  • Q-dots quantum dots
  • the mean fluorescence of Q-dots loaded particles was studied as a function of Tris concentration. The fluorescence signal on the particles increased as the Tris concentration increases. The concentration of 200 mM Tris gave the best effect in terms of loading and was therefore selected for all the subsequent experiments.
  • the loading capacity of “large porous” silicon particles was evaluated by using “small porous” silicon particles as the control.
  • the hydrodynamic size of Q-dots is 13-15 nm, and should not be able to get into the small pores ( ⁇ 5 nm) but stay on their surface.
  • the concentration effect of Q-dots for the loading was performed by changing the amount of Q-dots from 10 picomolar to 2 micromolar and incubating all the reactions in the same final volume (20 ⁇ l). Sample's loading was analyzed at FACS and the quantum dot concentration of 2 ⁇ M resulted in the highest level of loading and therefore used for all the subsequent experiments.
  • the kinetics of amino quantum dots release from LP oxidized particles were exponential like with a 33% decrease of the amount of loaded nanoparticles after 20 minutes and of 67.5% after 45 minutes. After 20 hours only a residual 1% of the initial fluorescence was found associated to the particles demonstrating that all the quantum dots could be released from the nanoporous silicon particles.
  • the fluorescence of a solution containing 35 ⁇ g/ml of FITC conjugated single wall carbon nanotubes (FITC-SWNTs) and of a serial dilution of them (ranging from 1:2 to 1:2048) in milliq pure water was measured ( FIG. 6A , Panel A).
  • the fluorescence values of the first 3 and more concentrated samples were lower than the values of less concentrated solution. This is a phenomenon known as fluorescence quenching.
  • As a control the same readings were performed with a series of solutions of carboxy pegylated quantum dots ranging from 8 ⁇ M to 4 nM that showed a linear decrease of the fluorescence value along with the dilution.
  • Nanoliposomes also loaded into LP particles with the same dynamics as described above.
  • the fluorescence associated with the Silicon particles were visualized by means of fluorescence microscopy ( FIG. 8A , Panels A and B, FIG. 8B , Panels E and F).
  • Porous Silicon is known to be fully biodegradable (Mayne 2000; Low, Williams et al. 2006) and biocompatible (Canham 1995).
  • the oxidation process that was performed according with protocols already described for Silicon wafers (Canham 1997), introduced hydroxil groups (OH) on the exposed Silicon surface and these groups, in the presence of water, are subjected to hydrolysis thus converting solid Silicon into highly soluble Silicic acid.
  • the characterization of nanoporous Silicon particles degradation was performed through several techniques. The measurement of a decrease in the number of particles and in their volume was performed with Z2 Coulte® Particle Counter and Size Analyzer (Beckman Coulter). The particles were kept for 24 hours in a rotating wheel (8 rpm) at 37° C. in two different solution: TRIS 2.5 mM, 0.9% NaCl at pH7.3 (Saline) and Cell Culture Media with 10% FBS (CCM). To understand, if the size of the pores had a role in the degradation kinetics, both Silicon particles with smaller pores of 7-10 (SP) nanometers and particles with larger pores of 20-30 nanometers (LP) were used.
  • SP 7-10
  • LP nanometers
  • the readings at the ICP showed a linear increase in the amount of silicon present after degradation. These data confirmed the ability of the ICP-AES method for verification of degradation. The data were regular, with low standard deviations, and had a strong correlation with the Z2 readings of particles count and size during the test. The increased degradation that occurred in cell culture media as opposed to TRIS buffer suggested high biodegradability of these particles in cell culture conditions ( FIG. 12A , Panels A-B and FIG. 12B , Panels C-D).
  • Silicon nanoporous particles induced cell toxicity by means of Lactate Dehydrogenase (LDH) toxicity assay (Biovision Inc.), cell proliferation by means of MTT assay (Promega) and apoptosis and cell cycle by means of Propidium Iodide staining.
  • LDH Lactate Dehydrogenase
  • MTT MTT assay
  • apoptosis and cell cycle by means of Propidium Iodide staining.
  • FIG. 13 Panels A-D
  • the cells were at 50% confluency after 12 hours and they reached almost 100% confluency after 24 hours.
  • Some signs of apoptosis or, more generally, of cell death were visible at 48 hours and even more at 72 hours (bright, rounded, reflectant cells or cells with large, multilobular nuclei or with high narrowing of the cell body) as indicated by the white arrows in the FIG. 13 , Panels A-D. This was mainly due to the fact that the cells had already reached confluency and could not find any space to grow further and thus underwent some processes of cell degradation.
  • LDH is a cytoplasmic enzyme that is released into the cytoplasm upon cell lysis.
  • the LDH assay therefore, is a measure of membrane integrity.
  • the basis of the LDH assay are oxidization of lactate to pyruvate by LDH, pyruvate reaction with the tetrazolium salt to form formazan, and the spectrophotometrical detection of the water-soluble formazan.
  • a toxicity calibration curve ( FIG. 14A , Panel A) was made to correlate the absorbance values read at fluorimeter with the number of cells that were lysed by 1% Triton incubation. From this calibration curve, the amount of cells that were releasing the LDH enzyme during particles incubation was derived. At 12 and 24 hours, the toxicity signal was very low and could be mainly due to unbound cells that did not recover from trypsinization and seeding (background toxicity). This was confirmed by comparing the toxicity values coming from the experimental plates with those measured in the control plates ( FIG. 14A , Panel B). The toxicity of HUVEC cells grown in the 96 well plates without any particles (positive control) showed at 72 hours a mean absorbance of 0.496 at 470 nm.
  • MTT is a yellow water-soluble tetrazolium dye that is reduced by live cells to a water insoluble purple formazan.
  • the amount of formazan may be determined by solubilizing it in DMSO and measuring it spectrophotometrically. Comparisons between the spectra of treated and untreated cells may give a relative estimation of cytotoxicity. (Alley et al. (1988) Cancer Res. 48:589-601).
  • a toxicity calibration curve ( FIG. 15 , Panel A) to correlate the absorbance values read at fluorimeter with the number of growing cells. From this calibration curve, the amount of cells that were metabolically active was derived.
  • HUVEC cells exposed for 12, 24, 48 and 72 hours to a 1:5 ratio of particles were analyzed after fixation and propidium iodide staining at FACS.
  • the forward scattering (FSC) and side scattering (SSC) in a dot plot and in a contour plot were first analyzed ( FIG. 16 , Panels A-C).
  • FSC parameter provided an information of the size of the cells while SSC provided an information of the shape of the cells.
  • HUVEC cells were incubated with CCM containing the degradation product of all the particles type and confirmed the results described so far ( FIG. 17D ).
  • a slight increase was measured in the amount of cells in the apoptotic region when the cells were incubated for 72 hours with the degradation product of SP oxidized and SP and LP APTES modified particles. It may be possible that smaller Silicon fragments produced during the degradation process induced some kind of toxicity 45 -48.
  • a multi-stage delivery system based on biodegradable silicon particles containing nanopores of specific size as first stage carriers that may load, carry, release and deliver into cells multiple types of nanoparticles with a precise control was developed.
  • the first stage silicon nanoporous particles may be simultaneously loaded with different types of second stage nanoparticles, which are released in a sustained fashion over time.
  • the major physical, chemical, and electrostatic mechanisms that control the loading and release of second stage nanoparticles were defined.
  • the porous silicon carriers are able to locally delivery the second stage nanoparticles into the cytoplasm.
  • nanotechnology Since its development in the last decade, nanotechnology has being used in a wide variety of applications in biomedical research for disease detection, diagnosis, and treatment 1-3 .
  • the objectives of many studies involving the development and refinement of nanoparticles have focused on their use as agents for delivery of therapeutic or imaging molecules to organs, tissues, and cells 4,5 .
  • a number of different nanovectors have been evaluated for therapeutic uses, including liposomes of various sizes and composition 6,7 , quantum dots (Q-dots) 8,9 , iron oxide 10 , single wall carbon nanotubes (SWNTs) 11 , gold nanoshells 12,13 and several other types of nanoparticles 14 .
  • the progress thus far has given rise to the field defined as “molecularly targeted therapeutics” 15-18 , however the accomplishment of the original objective, which is to selectively deliver a therapeutic agent using a nanovector-based delivery system, has not been fully realized 19,20 .
  • nanovectors into nanoporous silicon particles may allow the nanovectors to evade the natural biological barriers that may normally retard their therapeutic effects. Such approach may provide protection of therapeutic agents from surrounding fluids and molecules that may normally degrade them prematurely and from uptake by the Reticulo Endothelial System (RES). This may lead to a greater stability of the active agents, while providing increased delivery and concentrated dosage of therapeutic agents to a targeted tissue.
  • RES Reticulo Endothelial System
  • the multiple and simultaneous loading of second stage nanoparticles into first stage silicon nanoporous particles was achieved.
  • the second stage particles (Q-dots and SWNTs) were slowly released over time periods sufficient for the first stage particle to reach a specific biological target site.
  • the main physical, chemical and electrostatic mechanisms that govern the loading and release processes were.
  • the nanodelivery system was able to locally release its payload into cells.
  • FIG. 19 Panels a and b, show representative SEM images of the back and front sides and of the cross sections of “large pore” (LP) and “small pore” (SP) silicon particles respectively. These particles are highly porous and hemispherical in shape.
  • the diameter of LP particles is approximately 3.5 ⁇ m, with pores of straight profile, which cross the particles perpendicularly to their external surface and have pore size ranging from 20 to 30 nm ( FIG. 19 , Panel a).
  • SP silicon particles have a mean diameter of 3.2 ⁇ m, and have a flatter shape than LP silicon particles as a consequence of anodization and electropolishing processes used to produce them, with pore sizes less than 10 nm ( FIG. 19 , Panel b). Both LP and SP silicon particles have a thickness of 0.5-0.6 ⁇ m. According to BET analysis, the surface area is 156 m2 g-1 for LP particles and 294 m 2 g ⁇ 1 for SP particles. Pore volume is 0.542 cm 3 g ⁇ 1 for LP particles and 0.383 cm3 g-1 for SP particles.
  • the pore density, size, shape and profile may be finely tuned by changing electrical current, etching time, and doping, which is reproducible from batch to batch.
  • Non-oxidized silicon is a hydrophobic material but a variety of surface treatment protocols are available for silicon-based materials to be stabilized and further functionalized with oligonucleotides 27 , biomolecules 28 , antibodies 29,30 , and polyethylene glycol (PEG) chains 31 .
  • Oxidized silicon particles have a negative zeta potential value ( ⁇ 10.1 for LP; ⁇ 11-25 for SP) due to the presence of the hydroxyl groups on the surface of the particles 32 .
  • the particles that were modified with APTES have a positive zeta potential value (6.52 for LP; 6.45 for SP) as a consequence of the introduction of amino groups on their surface.
  • the hydrodynamic size of Q-dots was measured by the diffusion coefficient of colloidal in solution using dynamic light scattering technique. Diameter was 13 nm for Amino-PEG Q-dots, and 16 nm for Carboxyl Q-dots. Size of PEG-FITC-SWNTs was evaluated by AFM microscopy. The diameter of non PEGylated SWNTs is around 1 nm but due to the PEG surrounding the nanotubes, PEG-FITC-SWNTs used for this study had a mean diameter of 4 nm, and a mean length of 30 nm. The SWNTs were functionalized using PEG-amine through carboxylic acids obtained via the SWNT cutting process and were conjugated to FITC to allow for their fluorescent imaging.
  • Second stage nanoparticles with fluorescent properties were selected to quantify loading into and release from silicon nanoporous particles using established techniques, such as flow cytometry, fluorimetry, as well as both fluorescence and confocal microscopy. Physical and chemical of first and second stage particles are summarized in Table 6.
  • Protocols to efficiently load nanoparticles inside the pores of first stage silicon particles were developed.
  • One of the factors affecting the loading process was the amount of second stage particles in the media surrounding the particles.
  • concentration of the second stage particles By raising the concentration of the second stage particles, progressively higher levels of loading were achieved as assessed by flow cytometry ( FIG. 20 , Panels A and B) and by direct visualization with fluorescent microscopy ( FIG. 20 , Panels C and D).
  • FIG. 21 Panels a and c illustrate the results obtained when LP oxidized silicon particles and LP APTES modified silicon particles were incubated with a fixed amount of both Amino and Carboxyl Q-dots and PEG-FITC-SWNTs. Complete loading of the first stage porous silicon particles occurred within 15 min if the combination of first stage porous silicon particles and second stage particles matched the electrostatic criteria described above. The loading of SP oxidized silicon particles and SP APTES modified silicon particles with second stage nanoparticles was also evaluated ( FIG. 21 , Panels c and d, respectively).
  • Q-dots size was between 13 and 16 nm so they could not be loaded into the pores of SP silicon particles (5-7 nm).
  • the pores of LP silicon particles (20-40 nm) were sufficiently large to allow Q-dots loading.
  • SP particle mean fluorescence was only 6% of LP particles.
  • the smaller size of the PEG-FITC-SWNTs was compatible with SP particle pores, resulting in increased loading (25% of the PEG-FITC-SWNTs loaded into the LP silicon particles).
  • FIG. 21 Panels e-h, demonstrate that both types of second stage particles were released over time from the first stage silicon particles. Surprisingly, the release process was sustained, with complete release reached after 20 hours. In addition, the release kinetics significantly differed between Q-dots and PEG-FITC-SWNTs, with Q-dots being released significantly faster than SWNTs.
  • FIG. 22 Panels a-b, show a series of 3 dimensional projections and rotations of LP APTES silicon particles loaded with Carboxyl Q-dots. A more intense fluorescence signal was detected in the central region of the back face of the silicon particles, where larger pores are, see FIG. 19 , Panel a. The less intense signal coming from the surrounding areas was due either to partial loading into smaller pores or by the interaction of Q-dots with the surface of the silicon particle.
  • Silicon is widely used in the microelectronics industry, and has demonstrated its capacity for mass production of microchips as well as for the development of biosensors, implantable devices, and drug delivery systems 36-39 . While bulk silicon remains inert in physiological buffer, porous silicon has a high degree of biodegradability with degradation kinetics that may be finely tuned between hours to days according to pore size density 40,41 . Porous silicon particles degrades to silicic acid, which is harmless to the body and we have found that neither whole intact silicon particles nor their degradation products are cytotoxic for cells.
  • the fabrication protocols may allow the manufacturing of silicon particulates of any desired shape, size (dimensions from 100 nm to hundreds of ⁇ m), pore size (5-100 nm), and/or pore density.
  • the present studies provide evidence of the ability of efficient loading of nanoporous silicon particles with second stage nanoparticles of different natures, sizes, and shapes.
  • the loading process may be regulated by adjustment of the concentration of nanoparticles and/or by taking advantage of the chemical surface properties of either or both first and second stage particles.
  • the dynamics of nanoparticle release and explored the ability of the nanoporous silicon particles to be loaded with multiple types of nanoparticles simultaneously has been shown in the present studies. These studies have clearly demonstrated that the Q-dots and PEG-FITC-SWNTs used as second stage particles may localize to different compartments of the first stage silicon nanoporous particle carriers according to the size and chemical properties of the second stage particles.
  • the relative size of the pores of the silicon particles and of the second stage particles together may determine the most successful configuration of the combination of first and second stage particles ( FIG. 25 , Panel A). Concentration of the second stage nanovectors influences the efficiency of the loading process, which may be regulated both by passive diffusion and capillary convection of the second stage particles into the nanopores of the silicon particles. Hydrodynamic interactions of the second stage nanovectors with the nanopores of the silicon particles and Brownian motion affects stability of the assembled system and the time that the second stage nanovectors remain loaded inside the nanopores of the first stage silicon particles ( FIG. 25 , Panel B).
  • a third mechanism that may be considered is the electrostatic interaction between the first stage silicon particle carrier and the second stage nanovectors ( FIG. 25 , Panel C).
  • each of these features may allow the fine tuning of the amount of second stage nanovectors that may be loaded into the first stage nanoporous silicon particles, which may be matched to a specific pharmacological need in future applications of drug delivery.
  • the original and unique properties of the multi-stage nanocarrier system may allow multiple therapeutic agents, penetration enhancers or imaging contrast agents to be delivered for the simultaneous detection and then destruction of tumors or for imaging and then treatment of other pathological conditions.
  • a heavily doped p++type Si(100) wafer with a resistivity of 0.005 ohm cm ⁇ 1 (Silicon Quest International, Santa Clara, Calif., USA) was used as the substrate.
  • the wafer was then placed in a home-make Teflon cell for electrochemical etching.
  • the silicon particles with large pores (LP) were formed in a mixture of hydrofluoric acid (49% HF) and ethanol (3:7 v/v) by applying a current density of 80 mA cm ⁇ 2 for 25 s.
  • a high porosity layer was formed by applying a current density of 320 mA cm ⁇ 2 for 6 s.
  • SP silicon particles with small pores
  • SP silicon particles with small pores
  • the high porosity layers were formed by applying a current density of 320 mA cm ⁇ 2 for 6 s in an HF:ethanol mixture with a ratio of 2:5 (v/v). After removing the nitride layer by HF, particles were released by ultrasound in isopropyl alcohol (IPA) for 1 min. The IPA solution containing porous silicon particles was collected and stored at 4° C.
  • the nitrogen adsorption desorption volumetric isotherms obtained at 77 K were measured on a Quantachrome Autosorb-3b BET Surface Analyzer. The samples were baked at 150° C. in vacuum overnight. Particle surface area was obtained by BET linearization in the pressure range 0.05 to 1 P/P0. For the LP particles, the BET surface area was 156 m 2 g ⁇ 1 and pore volume was 0.54 cm3 g-1 using nitrogen adsorption-desorption isotherm measurements. The average pore size was estimated to be about 24.2 nm. For SP particles, the BET surface area was measured 294 m 2 g-1; pore volume was 0.38 cm3 g 31 1 and the average pore size was 7.4 nm.
  • Particles were counted using a Z2 Coulter® Particle Counter and Size Analyzer (Beckman Coulter, Fullerton, Calif., USA), with a 50 ⁇ m aperture size. The upper and lower size limits for analysis were set at 1.8 and 3.6 ⁇ m. For analysis, particles were suspended in the balanced electrolyte solution (ISOTON® II Diluent, Beckman Coulter Fullerton, Calif., USA) and counted. The total volume of original suspension of particles did not exceed 0.3% of the final analysis volume. The particle counter displays the concentration of particles in the solution as well an analysis of the particle size distribution.
  • Silicon microparticles in IPA were dried in a glass beaker by heating (80-90° C.) and then oxidized them in a piranha solution (1:2 H 2 O 2 :concentrated H 2 SO 4 (v/v)).
  • the particles were added to a solution of H 2 O 2 (30%), sonicated in a 5510R-MT ultrasonic cleaner (BRANSONIC, Danbury, Conn., USA) for 30 s and then H 2 SO 4 (95-98%) was added and the suspension was heated to 100-110° C. for 2 h, with intermittent sonication to disperse the particles.
  • the particles were then washed with deionized (DI) water.
  • DI deionized
  • Washing of the particles in DI water involves centrifugation of the particulate suspension at 4,200 rpm for 5 min followed by removal of the supernatant and resuspension of the particles in DI water.
  • the oxidized silicon particles were stored at 4° C. in DI water until further use.
  • the oxidized silicon particles Prior to silanization, the oxidized silicon particles were hydroxylated in 1.5 M HNO 3 for approximately 1.5 h. The particles were then washed 3-5 times with DI water followed by 2 washes with IPA. The silicon particles were then suspended in IPA containing 0.5% (v/v) APTES for 45 min at room temperature. The particles were then washed with IPA (4,200 g for 5 min, 5 times), and stored in IPA at 4° C.
  • Q-dots were purchased from Invitrogen (Carlsbad, Calif., USA). In this study, we used Amino-PEG with 525 nm and 565 nm emission wavelength (catalogue number Q21541MP and Q21531MP respectively) and Carboxyl Q-dots with 525 nm and 565 nm emission wavelength (catalogue number Q21341MP and Q21331MP respectively).
  • Hydrazine monohydrate (10 mL) was added to and the solution was heated to reflux under nitrogen for 12 h to give a terminal primary amine on the end of the PEGylated US-SWNT.
  • the product was purified by dialysis in DI water for 5 days.
  • the solution was then transferred to a round bottom flask wrapped in foil and FITC (0.12 g) predissolved in a small amount of DMF was added to the H 2 H-PEG-US-SWNT solution.
  • the reaction was stirred at room temperature for 12 h.
  • the solution was transferred to a dialysis bag and was kept in continuous dialysis with DI water in the dark for 5 days followed by filtration through glass wool to remove the undissolved particulates.
  • the final product FITC-PEG-US-SWNT contained some FITC physisorbed to the PEG-US-SWNTs instead of being covalently attached. Most of the physisorbed FITC still remains associated with the SWNTs after months of dialysis in water.
  • the zeta potential of the silicon particles, Q-dots, and FITC-PEG-US-SWNTs were analyzed using a Zetasizer nano ZS (Malvern Instruments Ltd., Southborough, Mass., USA). The particles were suspended in 20 mM Tris(hydroxymethyl)aminomethane (TRIS-HCL) buffer (pH 7.3) for the analysis.
  • TMS-HCL Tris(hydroxymethyl)aminomethane
  • the silicon nanoporous particles that were used in development of the multi-stage nanodevice include LP oxidized porous silicon, SP oxidized porous silicon and APTES modified LP and SP particles.
  • the second stage particles include Amino-PEG Q-dots, Carboxyl Q-dots, and PEG-FITC-SWNTs.
  • Initial experiments were performed to titrate the loading of the second stage particles into the first stage silicon particles. For each experimental point of the titration experiments, 3.0 ⁇ 105 silicon particles were used, which were resuspended in low binding polypropylene micro centrifuge tubes (VWR International, West Chester, Pa., USA) containing 3 ⁇ l DI water.
  • TRIS-HCl solution was adjusted at pH 7.3.
  • Either 2 ⁇ M Q-dots (5 ⁇ l) or 20 ng/ ⁇ l PEG-FITC-SWNTs (9 ⁇ l) were added to the TRIS-HCl solution, with 20 ⁇ l as the final volume for the loading experiments.
  • Samples were incubated by being placed on a rotating wheel (20 rpm) for 15 min at 25° C. After incubation, the samples were diluted with 20 mM TRIS-HCl, pH 7.3 to a volume of 150 ⁇ l and promptly examined for fluorescence intensity using a FACScalibur (Becton Dickinson) flow cytometer.
  • FACScalibur Becton Dickinson
  • LP silicon particles (2.1 ⁇ 106), which were either oxidized or APTES modified, were combined with 2 ⁇ M Amino-PEG Q-dots or Carboxyl Q-dots in a 200 mM TRIS-HCl solution at pH 7.3 or with 20 ng/ ⁇ l PEG-FITC-SWNTs in a 20 mM TRIS-HCl solution at pH 7.3 or with both 1 ⁇ M Q-dots and 10 ng/ ⁇ l PEG-FITC-SWNTs in a 50 mM TRIS-HCl solution at pH 7.3.
  • the final incubation volume for all studies was 140 ⁇ l.
  • first stage silicon particle carriers and second stage particles were incubated using a rotating wheel (20 rpm) for 15 min at 25° C.
  • the solution containing the first stage silicon particles and second stage particles were then washed in 1.4 mL DI H 2 O, and then centrifuged for 5 min at 4,200 rpm in a Beckman Coulter Allegra X-22 centrifuge. Pellets present after centrifugation were then resuspended in 70 ⁇ l of DI H 2 O and 10 ⁇ l was removed from each vial to assess the fluorescence of the samples using flow cytometry. Fluorescence was recorded at time 0 and then over 6 time points, which included 30, 60, 90, 180, 360, and 1,200 min.
  • the residual 60 ⁇ l left in each vial was diluted to 3 ml in 20 mM TRIS-HCl 0.9% NaCl release buffer, followed by incubation using a rotating wheel (20 rpm) for the given amount of time (30, 60, 90, 180, 360 and 1,200 min) at 37° C. At each time point, samples were centrifuged for 5 min at 4,200 rpm and the fluorescence evaluated using flow cytometry.
  • Particles were assessed for fluorescence using a FACScalibur (Becton Dickinson). Bivariate dot-plots defining logarithmic side scatter (SSC) versus logarithmic forward scatter (FSC) were used to evaluate the size and shape of the silicon particles (3 ⁇ m in diameter, 1.5 ⁇ m in height) and to exclude non-specific events from the analysis. Control rainbow BD CalibriteTM beads (3.5 ⁇ m in size) were used to calibrate the instrument. A polygonal region (R1) was defined as an electronic gate around the centre of the major population of interest, which excluded events that were too close to the signal-to-noise ratio limits of the cytometer. For each sample, the number of particles detected within the R1 region was above 90%.
  • GMFI geometric mean fluorescence intensity
  • the morphology of the silica particles was acquired using scanning electron microscopy (SEM, model LEO1530). Particles were directly placed on SEM samples stage and dried. For the particles tested in the high salt buffers, a mild washing step in DI water was performed before putting on the stage. The acceleration voltage was 10 kV.
  • AFM samples were prepared by deposition from DMF onto a freshly cleaved mica surface. Samples were spin coated and sectional analysis was used to determine the heights of each sample. AFM samples were obtained using tapping mode.
  • Particles were analyzed in bright field contrast with an Olympus CKX41 microscope with a 40 ⁇ magnification lens. Images were taken with an SP-350 Olympus True-Pic TURBO Image Processor camera.
  • Fluorescent imaging of particles was performed with a Nikon Eclipse TE2000-E with a DQC-FS Nikon CCD Camera kept at ⁇ 30.1° C. All the samples were mounted immediately before the analysis and the images acquired with a 63 ⁇ immersion oil objective. The microscope settings were kept constant throughout all the experiments. numerical aperture was set at 1.4, refractive index at 1.515, exposure time at 500 ms, readout Speed at 10 MHz and conversion gain at 1 ⁇ 6 ⁇ .
  • Fluorescently labeled siRNA loaded DOPC liposomes (original siRNA concentration: 100 ng/ ⁇ l), as second stage particles, were mixed with 1st stage large pore “LP” oxidized silicon particles (3.5 micron). Incubation was performed in 20 mM Tris pH 7.3 for 30 min at room temperature. The solution was spun down at 4,200 rpm for 1 min at room temperature. The supernatant was recovered and the fluorescence of the sample was measured by fluorimetry using 544 nm/590 nm (excitation/emission) settings. The particle pellet comprising the 1st stage particles that had incorporated the fluorescent liposomes were resuspended in 100 ⁇ l of deionized water and fluorimetric readings were taken.
  • FIG. 8B Panel D
  • Panels E and F show fluorescent microscopy images visualizing second stage liposomes containing Alexa 555 labeled SiRNA into 3.5 micron nanoporous silicon first stage particles LP in white field and red field respectively
  • Alexa 555 fluorescently labeled siRNAs were encapsulated into liposomes and loaded into the 1st stage porous silicon particles.
  • Liposomes with a lipid composition of 58:40:2 Liposomes with a lipid composition of 58:40:2 (Mol %) DPPC:Cholesterol:DSPE-Methoxy PEG (2000) respectively may be made by the extrusion process as follows: Briefly, the lipids may be dissolved in ethanol at 55° C. The dissolved lipids may then be hydrated with 300 mM ammonium sulfate solution (for 15-30 minutes) to facilitate active loading of doxorubicin, see Li, et al. Biochim et Biophys Acta 1415 (1998). Liposomes may be extruded through a series of Nuclepore track-etched polycarbonate membranes of decreasing pore sizes.
  • the liposomes may then be extruded 5 times through a 0.2 ⁇ m membrane. This may be followed by an extrusion through 0.1 ⁇ m membrane (5 times), then through a 0.05 ⁇ m membrane (5 times). The final extrusion may be through a 0.03 ⁇ m membrane (10 times). The extrusions may be carried out at 55° C.
  • Produced fluorescently labeled liposomes contained 30% of DiPalmitoylPhosphatidylCholine (DPPC) lipids, 30% of cholesterol, 10% of fluorescently labeled lipid N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl]dipalmitoyl-L- ⁇ -phosphatidylethanolamine (NBD-PE) lipid mixed with either 30% 1,2-Dioleyl-3-trymethylammoniumpropane (DOTAP) (for cationic liposomes), or 30% dioleoylphosphatidyl glycerol (DOPG) (for anionic liposomes), or 30% dioleoylphosphatidyl choline DOPC (for neutral liposomes).
  • DOTAP 1,2-Dioleyl-3-trymethylammoniumpropane
  • DOPG dioleoylphosphatidyl glycerol
  • DOPG dioleoylphosphatidyl
  • Neutral liposomes had initial mean diameter 47.4 nm and mean diameter after 3 days 78.2 nm as determined by Dynamic Light Scattering (DLS). Zeta potential of neutral liposomes was ⁇ 13.04 ⁇ 0.77 mV.
  • Cationic liposomes had initial mean diameter 49.6 nm and mean diameter after 3 days 58.2 nm as determined by DLS. Zeta potential of cationic liposomes was 30.30 ⁇ 2.55 mV.
  • FIG. 8A Panel A, shows confocal microscopy images of neutral (left) and cationic (right) fluorescently labeled liposomes loaded into 1 micron XLP APTES modified silicon particles.
  • FIG. 8A , Panel C shows Excel quantification of fluorescently labeled liposome loading.
  • the liposomes may be dialyzed overnight against 150 mM NaCl to remove unencapsulated ammonium sulfate to generate a trans-membrane proton gradient.
  • Doxorubicin ( ⁇ 10 mg/ml) may be added to the liposomes at 60° C. for 1 hr. The drug:lipid ratio will be 0.2:1.0 and the final lipid concentration will be ⁇ 25 mM.
  • the resulting liposomal formulation may be kept on ice for 15 minutes to stop the remote loading process.
  • the liposomes may be dialyzed overnight against 150 mM NaCl to remove unencapsulated doxorubicin.
  • the final encapsulated Doxorubicin concentration may be determined by lysis with methanol (30% of final volume) and measuring the UV absorbance at 480 nm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/836,004 2006-08-08 2007-08-08 Multistage delivery of active agents Abandoned US20080311182A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US11/836,004 US20080311182A1 (en) 2006-08-08 2007-08-08 Multistage delivery of active agents
PCT/US2008/061775 WO2008134637A1 (en) 2007-04-27 2008-04-28 Porous particles and methods of making thereof
EP08780571A EP2150493A1 (en) 2007-04-27 2008-04-28 Porous particles and methods of making thereof
JP2010506558A JP2010526652A (ja) 2007-04-27 2008-04-28 多孔性粒子およびその製造方法
CN2008800220199A CN101778796B (zh) 2007-04-27 2008-04-28 多孔颗粒及其制备方法
KR1020097024739A KR20100051591A (ko) 2007-04-27 2008-04-28 다공질 입자 및 이의 제조 방법
US12/110,515 US8920625B2 (en) 2007-04-27 2008-04-28 Electrochemical method of making porous particles using a constant current density
AU2008245496A AU2008245496A1 (en) 2007-04-27 2008-04-28 Porous particles and methods of making thereof
CA2685544A CA2685544C (en) 2007-04-27 2008-04-28 Porous particles and methods of making thereof
JP2012196070A JP2013034991A (ja) 2007-04-27 2012-09-06 多孔性粒子およびその製造方法
US14/538,065 US10253424B2 (en) 2007-04-27 2014-11-11 Porous particles and methods of making thereof
US14/725,570 US10143658B2 (en) 2006-08-08 2015-05-29 Multistage delivery of active agents
US16/158,644 US20190111000A1 (en) 2006-08-08 2018-10-12 Multistage delivery of active agents
US17/368,401 US20210338593A1 (en) 2006-08-08 2021-07-06 Multistage delivery of active agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82175006P 2006-08-08 2006-08-08
US91434807P 2007-04-27 2007-04-27
US11/836,004 US20080311182A1 (en) 2006-08-08 2007-08-08 Multistage delivery of active agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/110,515 Continuation-In-Part US8920625B2 (en) 2007-04-27 2008-04-28 Electrochemical method of making porous particles using a constant current density
US14/725,570 Continuation US10143658B2 (en) 2006-08-08 2015-05-29 Multistage delivery of active agents

Publications (1)

Publication Number Publication Date
US20080311182A1 true US20080311182A1 (en) 2008-12-18

Family

ID=39082940

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/836,004 Abandoned US20080311182A1 (en) 2006-08-08 2007-08-08 Multistage delivery of active agents
US14/725,570 Active US10143658B2 (en) 2006-08-08 2015-05-29 Multistage delivery of active agents
US16/158,644 Abandoned US20190111000A1 (en) 2006-08-08 2018-10-12 Multistage delivery of active agents
US17/368,401 Pending US20210338593A1 (en) 2006-08-08 2021-07-06 Multistage delivery of active agents

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/725,570 Active US10143658B2 (en) 2006-08-08 2015-05-29 Multistage delivery of active agents
US16/158,644 Abandoned US20190111000A1 (en) 2006-08-08 2018-10-12 Multistage delivery of active agents
US17/368,401 Pending US20210338593A1 (en) 2006-08-08 2021-07-06 Multistage delivery of active agents

Country Status (9)

Country Link
US (4) US20080311182A1 (xx)
EP (1) EP2056794A4 (xx)
JP (1) JP2010500375A (xx)
CN (1) CN101652126B (xx)
AU (1) AU2007286203B2 (xx)
CA (1) CA2664919A1 (xx)
HK (1) HK1140139A1 (xx)
MX (1) MX2009001461A (xx)
WO (1) WO2008021908A2 (xx)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102030A1 (en) * 2006-10-11 2008-05-01 Decuzzi Paolo Particles for cell targeting
US20080206344A1 (en) * 2007-02-26 2008-08-28 Board Of Regents Of The University Of Texas System Endocytotic particles
US20080280140A1 (en) * 2007-04-27 2008-11-13 Mauro Ferrari Porous particles and methods of making thereof
US20100209538A1 (en) * 2009-02-18 2010-08-19 Cipolla David C Ph-modulated formulations for pulmonary delivery
US20100285052A1 (en) * 2009-05-05 2010-11-11 Mullis Kary B Chemically Programmable Immunity
US20110070307A1 (en) * 2004-12-17 2011-03-24 Evgenia Mandrusov Tissue regeneration
WO2011038111A1 (en) * 2009-09-23 2011-03-31 Crystalplex Corporation Passivated nanoparticles
WO2011086210A1 (es) * 2009-12-22 2011-07-21 Universidad Autónoma de Madrid Partículas magnético-luminiscentes para aplicaciones biomédicas
US20110213193A1 (en) * 2008-08-28 2011-09-01 The Florida International University Board Of Trustees Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier
WO2011116219A1 (en) * 2010-03-17 2011-09-22 Board Of Regent Of The University Of Texas System Theranostic delivery systems with modified surfaces
US20110311452A1 (en) * 2008-12-23 2011-12-22 Board Of Regents Of The University Of Texas System Inflammation targeting particles
WO2012040331A2 (en) * 2010-09-21 2012-03-29 The General Hospital Corporation Multistage nanoparticles
US20120121516A1 (en) * 2009-07-17 2012-05-17 Centre National De La Recherche Scientifique- Cnrs Emulsion Activatable by Ultrasounds and Method for Producing Same
WO2012074440A2 (ru) * 2010-12-01 2012-06-07 Учреждение Российской Академии Наук Институт Кристаллографии Им. А.В.Шубникова Ран Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
US20130195759A1 (en) * 2008-04-25 2013-08-01 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US20130195963A1 (en) * 2011-12-07 2013-08-01 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US8568877B2 (en) 2010-03-09 2013-10-29 Board Of Regents Of The University Of Texas System Porous and non-porous nanostructures
US20140010879A1 (en) * 2012-06-12 2014-01-09 The Methodist Hospital Research Institute Compositions and methods of treating therapy resistant cancer and uses thereof
WO2014036019A2 (en) * 2012-08-27 2014-03-06 Red Lion Chem Tech, Llc Methods and compositions for heavy metal removal and for oral delivery of desirable agents
US20140127305A1 (en) * 2011-04-14 2014-05-08 The Regents Of The University Of California Multifunctional nanoparticle designs and applications
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
US20140296836A1 (en) * 2011-09-27 2014-10-02 Board Of Regents, The University Of Texas System Gold-in-silicon nanoassembly for thermal therapy and methods of use
US8859004B2 (en) 2011-08-04 2014-10-14 Nano And Advanced Materials Institute Limited pH-sensitive nanoparticles for oral insulin delivery
US20140356441A1 (en) * 2013-05-31 2014-12-04 Ricoh Company, Ltd. Core-shell type particles and method for producing the same
US9028797B2 (en) 2010-02-26 2015-05-12 Nagasaki University Composite body for antigen or drug delivery
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
WO2015176025A1 (en) 2014-05-15 2015-11-19 The Methodist Hospital Discoidal polymeric nanoconstructs and methods of use in cancer theranostics
US9216155B2 (en) 2010-01-19 2015-12-22 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
WO2015066212A3 (en) * 2013-10-31 2015-12-30 University Of Hawaii Calpain inhibitors for ibd and colorectal cancer treatment
US9541480B2 (en) 2011-06-29 2017-01-10 Academia Sinica Capture, purification, and release of biological substances using a surface coating
US20170056327A1 (en) * 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
US20170136123A1 (en) * 2013-01-10 2017-05-18 Amrita Vishwa Vidyapeetham Stannous doped micro and nano particles for augmented radiofrequency ablation
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10058633B2 (en) 2010-07-09 2018-08-28 Board Of Regents Of The University Of Texas System Biodegradable scaffolds
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
US10208310B2 (en) 2014-10-06 2019-02-19 Exicure, Inc. Anti-TNF compounds
WO2019157319A1 (en) * 2018-02-12 2019-08-15 Flagship Pioneering Innovations V, Inc. Devices and methods for delivering material into a biological tissue or cell
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10495644B2 (en) 2014-04-01 2019-12-03 Academia Sinica Methods and systems for cancer diagnosis and prognosis
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
US10837018B2 (en) 2013-07-25 2020-11-17 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10995267B2 (en) 2014-05-29 2021-05-04 Crystalplex Corporation Dispersion system for quantum dots having organic coatings comprising free polar and non-polar groups
US20210205456A1 (en) * 2012-09-19 2021-07-08 Georgetown University Targeted liposomes
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11510995B2 (en) * 2015-12-21 2022-11-29 Fidia Farmaceutici S.P.A. Nanosystems for controlled transport of active molecules for diagnostic, prognostic and therapeutic purposes
US11633503B2 (en) 2009-01-08 2023-04-25 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
US11690920B2 (en) 2017-07-13 2023-07-04 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
US11859118B2 (en) 2016-05-19 2024-01-02 Tectus Corporation Cadmium-free quantum dots, tunable quantum dots, quantum dot containing polymer, articles, films, and 3D structure containing them and methods of making and using them
US11866700B2 (en) 2016-05-06 2024-01-09 Exicure Operating Company Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773303A2 (en) 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
JP2009533350A (ja) 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
US8173115B2 (en) 2008-07-29 2012-05-08 The Board Of Regents Of The University Of Texas System Particle compositions with a pre-selected cell internalization mode
KR20110039466A (ko) * 2008-07-29 2011-04-18 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 미리 선택된 세포 내재화 방식을 갖는 입자 조성물
CA2749467A1 (en) * 2009-01-15 2010-07-22 Board Of Regents Of The University Of Texas System Porous structures with modified biodegradation kinetics
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
KR20190006576A (ko) * 2010-08-16 2019-01-18 오스트레일리안 뉴클리어 사이언스 앤드 테크놀로지 오가니제이션 생체분자의 전달을 위한 세라믹 입자를 포함하는 미립자 물질 및 미립자 물질을 포함하는 약학적 조성물
EP2747774A4 (en) 2011-09-09 2015-02-11 Biomed Realty L P METHOD AND COMPOSITIONS FOR CONTROLLING VIRUS PROTECTION
US20130304050A1 (en) * 2012-05-10 2013-11-14 Wake Forest University Health Sciences Methods of treating cancerous tissue
JP2015536319A (ja) * 2012-10-16 2015-12-21 ウィリアム・マーシュ・ライス・ユニバーシティ 薬剤耐性を克服するための改善されたナノベクターベースの薬物送達システム
WO2016013751A1 (ko) 2014-07-22 2016-01-28 주식회사 레모넥스 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
EP3215176A4 (en) 2014-10-03 2018-05-23 Ntercept, LLC Compositions and methods for inhibiting the biological activity of soluble biomolecules
JP6894423B2 (ja) * 2015-07-09 2021-06-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 融合性リポソーム被覆多孔質ケイ素ナノ粒子
US10064855B2 (en) * 2016-03-08 2018-09-04 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
JP2020504177A (ja) * 2017-01-04 2020-02-06 ナノティックス，エルエルシー 捕捉粒子をアセンブルするための方法
CA3052561C (en) 2017-02-06 2023-02-14 Lemonex Inc. Physiologically active substance carrier
AU2018308332B2 (en) * 2017-07-25 2021-11-18 Lemonex Inc. Composition for delivering physiologically active ingredients into blood vessel
US11530132B2 (en) 2017-09-05 2022-12-20 Lemonex Inc. Composition comprising porous silica particles carrying a cell fate modulating factor
WO2019121748A1 (en) 2017-12-19 2019-06-27 Nanobiotix Nanoparticles for use for treating a neuronal disorder
JP2021507903A (ja) 2017-12-19 2021-02-25 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 脳の能力の向上又はストレスの処置に使用するためのナノ粒子
CN112546406B (zh) * 2020-11-20 2022-04-22 广东药科大学 一种微型机器人给药装置及给药系统
WO2024035784A1 (en) * 2022-08-10 2024-02-15 Auburn University Shrinking nanomaterial for biomedical applications

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099864A (en) * 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US20030059386A1 (en) * 2001-09-27 2003-03-27 Ceramoptec Industries, Inc. Topical application of chromophores for hair removal
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
US20050178287A1 (en) * 1998-11-20 2005-08-18 The General Hospital Corporation Permanent, removable tissue markings
US20080280140A1 (en) * 2007-04-27 2008-11-13 Mauro Ferrari Porous particles and methods of making thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US6395302B1 (en) * 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
ES2130056B1 (es) * 1997-01-16 2000-02-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad oral de drogas de dificil absorcion.
US6887493B2 (en) * 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
JP2009520989A (ja) 2005-12-20 2009-05-28 ザ オハイオ ステイト ユニバーシティ リサーチ ファウンデーション 分析法のためのナノ多孔性基材
US20090311295A1 (en) * 2006-05-12 2009-12-17 Edith Mathiowitz Particles with high uniform loading of nanoparticles and methods of preparation thereof
US20100074958A1 (en) * 2006-09-28 2010-03-25 Board Of Regents Of The University Of Texas System Methods and compositions for targeting fenestrated vasculature
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099864A (en) * 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US20050178287A1 (en) * 1998-11-20 2005-08-18 The General Hospital Corporation Permanent, removable tissue markings
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
US20030059386A1 (en) * 2001-09-27 2003-03-27 Ceramoptec Industries, Inc. Topical application of chromophores for hair removal
US20080280140A1 (en) * 2007-04-27 2008-11-13 Mauro Ferrari Porous particles and methods of making thereof

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070307A1 (en) * 2004-12-17 2011-03-24 Evgenia Mandrusov Tissue regeneration
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
US20080102030A1 (en) * 2006-10-11 2008-05-01 Decuzzi Paolo Particles for cell targeting
US8361508B2 (en) 2007-02-26 2013-01-29 Board Of Regents Of The University Of Texas System Endocytotic particles
US20080206344A1 (en) * 2007-02-26 2008-08-28 Board Of Regents Of The University Of Texas System Endocytotic particles
US8920625B2 (en) 2007-04-27 2014-12-30 Board Of Regents Of The University Of Texas System Electrochemical method of making porous particles using a constant current density
US10253424B2 (en) 2007-04-27 2019-04-09 Board Of Regents Of The University Of Texas System Porous particles and methods of making thereof
US20080280140A1 (en) * 2007-04-27 2008-11-13 Mauro Ferrari Porous particles and methods of making thereof
US9532948B2 (en) * 2008-04-25 2017-01-03 Northwestern University Nanostructure suitable for sequestering cholesterol and other molecules
US20130195759A1 (en) * 2008-04-25 2013-08-01 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
US20110213193A1 (en) * 2008-08-28 2011-09-01 The Florida International University Board Of Trustees Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier
US20110311452A1 (en) * 2008-12-23 2011-12-22 Board Of Regents Of The University Of Texas System Inflammation targeting particles
US11633503B2 (en) 2009-01-08 2023-04-25 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
WO2010096242A1 (en) * 2009-02-18 2010-08-26 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
US20100209538A1 (en) * 2009-02-18 2010-08-19 Cipolla David C Ph-modulated formulations for pulmonary delivery
RU2606175C2 (ru) * 2009-02-18 2017-01-10 Арадайм Корпорейшн pН-МОДУЛИРОВАННЫЕ СОСТАВЫ ДЛЯ ДОСТАВКИ В ЛЕГКИЕ
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
US8604184B2 (en) * 2009-05-05 2013-12-10 The United States Of America As Represented By The Secretary Of The Air Force Chemically programmable immunity
US20100285052A1 (en) * 2009-05-05 2010-11-11 Mullis Kary B Chemically Programmable Immunity
US20120121516A1 (en) * 2009-07-17 2012-05-17 Centre National De La Recherche Scientifique- Cnrs Emulsion Activatable by Ultrasounds and Method for Producing Same
WO2011038111A1 (en) * 2009-09-23 2011-03-31 Crystalplex Corporation Passivated nanoparticles
US9425253B2 (en) 2009-09-23 2016-08-23 Crystalplex Corporation Passivated nanoparticles
US11656231B2 (en) 2009-09-23 2023-05-23 Tectus Corporation Passivated nanoparticles
ES2367959A1 (es) * 2009-12-22 2011-11-11 Centro De Investigación Biomédica En Red En Bioingeniería, Biomateriales Y Nanomedicina Particulas magnético-luminiscentes para aplicaciones biomédicas.
WO2011086210A1 (es) * 2009-12-22 2011-07-21 Universidad Autónoma de Madrid Partículas magnético-luminiscentes para aplicaciones biomédicas
US10328026B2 (en) 2010-01-19 2019-06-25 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
US11285106B2 (en) 2010-01-19 2022-03-29 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
US9216155B2 (en) 2010-01-19 2015-12-22 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
US9028797B2 (en) 2010-02-26 2015-05-12 Nagasaki University Composite body for antigen or drug delivery
US8568877B2 (en) 2010-03-09 2013-10-29 Board Of Regents Of The University Of Texas System Porous and non-porous nanostructures
WO2011116219A1 (en) * 2010-03-17 2011-09-22 Board Of Regent Of The University Of Texas System Theranostic delivery systems with modified surfaces
WO2011116237A1 (en) * 2010-03-17 2011-09-22 Board Of Regents Of The University Of Texas System Universal cell-directed theranostics
US10058633B2 (en) 2010-07-09 2018-08-28 Board Of Regents Of The University Of Texas System Biodegradable scaffolds
WO2012040331A2 (en) * 2010-09-21 2012-03-29 The General Hospital Corporation Multistage nanoparticles
WO2012040331A3 (en) * 2010-09-21 2012-07-12 The General Hospital Corporation Multistage nanoparticles
WO2012074440A2 (ru) * 2010-12-01 2012-06-07 Учреждение Российской Академии Наук Институт Кристаллографии Им. А.В.Шубникова Ран Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
RU2475233C2 (ru) * 2010-12-01 2013-02-20 Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
WO2012074440A3 (ru) * 2010-12-01 2012-08-23 Учреждение Российской Академии Наук Институт Кристаллографии Им. А.В.Шубникова Ран Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
US20140127305A1 (en) * 2011-04-14 2014-05-08 The Regents Of The University Of California Multifunctional nanoparticle designs and applications
US9089498B2 (en) * 2011-04-14 2015-07-28 The Regents Of The University Of California Multifunctional nanoparticle designs and applications
US9744141B2 (en) 2011-04-14 2017-08-29 The Regents Of The University Of California Multifunctional nanoparticle designs and applications
US11674958B2 (en) 2011-06-29 2023-06-13 Academia Sinica Capture, purification, and release of biological substances using a surface coating
US9541480B2 (en) 2011-06-29 2017-01-10 Academia Sinica Capture, purification, and release of biological substances using a surface coating
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
US8859004B2 (en) 2011-08-04 2014-10-14 Nano And Advanced Materials Institute Limited pH-sensitive nanoparticles for oral insulin delivery
US20140296836A1 (en) * 2011-09-27 2014-10-02 Board Of Regents, The University Of Texas System Gold-in-silicon nanoassembly for thermal therapy and methods of use
US10220000B2 (en) 2011-11-08 2019-03-05 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
US20130195963A1 (en) * 2011-12-07 2013-08-01 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US8926994B2 (en) * 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US20210059942A1 (en) * 2012-06-12 2021-03-04 The Methodist Hospital Research Institute Compositions and methods of treating therapy resistant cancer and uses thereof
US20140010879A1 (en) * 2012-06-12 2014-01-09 The Methodist Hospital Research Institute Compositions and methods of treating therapy resistant cancer and uses thereof
US10842749B2 (en) * 2012-06-12 2020-11-24 The Methodist Hospital Research Institute Compositions and methods of treating therapy resistant cancer and uses thereof
WO2014036019A3 (en) * 2012-08-27 2014-04-17 Red Lion Chem Tech, Llc Methods and compositions for heavy metal removal and for oral delivery of desirable agents
US8883216B2 (en) 2012-08-27 2014-11-11 Red Lion Chem Tech, Llc Methods and ceramic nanoparticle compositions for heavy metal removal and for oral delivery of desirable agents
WO2014036019A2 (en) * 2012-08-27 2014-03-06 Red Lion Chem Tech, Llc Methods and compositions for heavy metal removal and for oral delivery of desirable agents
US11951167B2 (en) * 2012-09-19 2024-04-09 Georgetown University Targeted liposomes
US20210205456A1 (en) * 2012-09-19 2021-07-08 Georgetown University Targeted liposomes
US20170136123A1 (en) * 2013-01-10 2017-05-18 Amrita Vishwa Vidyapeetham Stannous doped micro and nano particles for augmented radiofrequency ablation
US20140356441A1 (en) * 2013-05-31 2014-12-04 Ricoh Company, Ltd. Core-shell type particles and method for producing the same
US10837018B2 (en) 2013-07-25 2020-11-17 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US20160279187A1 (en) * 2013-10-31 2016-09-29 University Of Hawaii Calpain inhibitors for ibd and colorectal cancer treatment
WO2015066212A3 (en) * 2013-10-31 2015-12-30 University Of Hawaii Calpain inhibitors for ibd and colorectal cancer treatment
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
US11883535B2 (en) 2013-12-03 2024-01-30 Northwestern University Liposomal particles, methods of making same and uses thereof
US10792251B2 (en) 2013-12-03 2020-10-06 Northwestern University Liposomal particles, methods of making same and uses thereof
US10495644B2 (en) 2014-04-01 2019-12-03 Academia Sinica Methods and systems for cancer diagnosis and prognosis
WO2015176025A1 (en) 2014-05-15 2015-11-19 The Methodist Hospital Discoidal polymeric nanoconstructs and methods of use in cancer theranostics
US10995267B2 (en) 2014-05-29 2021-05-04 Crystalplex Corporation Dispersion system for quantum dots having organic coatings comprising free polar and non-polar groups
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11123294B2 (en) 2014-06-04 2021-09-21 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11957788B2 (en) 2014-06-04 2024-04-16 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US10208310B2 (en) 2014-10-06 2019-02-19 Exicure, Inc. Anti-TNF compounds
US10760080B2 (en) 2014-10-06 2020-09-01 Exicure, Inc. Anti-TNF compounds
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10561611B2 (en) 2015-03-03 2020-02-18 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
US20170056327A1 (en) * 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
US11510995B2 (en) * 2015-12-21 2022-11-29 Fidia Farmaceutici S.P.A. Nanosystems for controlled transport of active molecules for diagnostic, prognostic and therapeutic purposes
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US10605708B2 (en) 2016-03-16 2020-03-31 Cellmax, Ltd Collection of suspended cells using a transferable membrane
US11866700B2 (en) 2016-05-06 2024-01-09 Exicure Operating Company Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
US11859118B2 (en) 2016-05-19 2024-01-02 Tectus Corporation Cadmium-free quantum dots, tunable quantum dots, quantum dot containing polymer, articles, films, and 3D structure containing them and methods of making and using them
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
US11690920B2 (en) 2017-07-13 2023-07-04 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
WO2019157319A1 (en) * 2018-02-12 2019-08-15 Flagship Pioneering Innovations V, Inc. Devices and methods for delivering material into a biological tissue or cell

Also Published As

Publication number Publication date
US10143658B2 (en) 2018-12-04
WO2008021908A2 (en) 2008-02-21
US20160051481A1 (en) 2016-02-25
CA2664919A1 (en) 2008-02-21
AU2007286203A1 (en) 2008-02-21
EP2056794A4 (en) 2012-12-26
AU2007286203A2 (en) 2009-03-19
EP2056794A2 (en) 2009-05-13
CN101652126A (zh) 2010-02-17
AU2007286203B2 (en) 2013-05-02
US20210338593A1 (en) 2021-11-04
HK1140139A1 (en) 2010-10-08
JP2010500375A (ja) 2010-01-07
MX2009001461A (es) 2009-07-02
CN101652126B (zh) 2013-07-17
WO2008021908A3 (en) 2008-08-14
US20190111000A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
US20210338593A1 (en) Multistage delivery of active agents
Li et al. Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy
Ashfaq et al. Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment
Bisso et al. Nanopharmaceuticals: A focus on their clinical translatability
A Santos et al. Multifunctional porous silicon for therapeutic drug delivery and imaging
Athar et al. Therapeutic nanoparticles: State-of-the-art of nanomedicine
Bazylińska et al. Nanoemulsion-templated multilayer nanocapsules for cyanine-type photosensitizer delivery to human breast carcinoma cells
Fattal et al. Nanomedicine technology: current achievements and new trends
Vauthier A journey through the emergence of nanomedicines with poly (alkylcyanoacrylate) based nanoparticles
ES2951598T3 (es) Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos
Lv et al. Biological and intracellular fates of drug nanocrystals through different delivery routes: Recent development enabled by bioimaging and PK modeling
JP2016531142A (ja) ナノ構造送達系を使用する細胞特異的ターゲティング
Son et al. Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration
Saharkhiz et al. A new theranostic pH-responsive niosome formulation for doxorubicin delivery and bio-imaging against breast cancer
Chen et al. A dual-targeting nanocarrier based on modified chitosan micelles for tumor imaging and therapy
Carissimi et al. Nanoparticles as drug delivery systems
Hnawate et al. Nanoparticle-novel drug delivery system: A Review
Ghazal et al. Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment
TWI472341B (zh) 寡聚物奈米顆粒複合體釋放系統
TWI483747B (zh) 口服式藥物載體及其製備方法
Ferrari et al. Multistage delivery of active agents
KR20130088081A (ko) 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법
Barbosa et al. Nanotechnology applied in drug delivery
Patel et al. Design and development of glutathione conjugated poly (d, l) lactide nanocarriers for delivery of hydrophilic fluorescent marker across blood brain barrier
Thorat et al. Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, OHI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FERRARI, MAURO;TASCIOTTI, ENNIO;SAKAMOTO, JASON;REEL/FRAME:020377/0154

Effective date: 20070918

Owner name: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FERRARI, MAURO;TASCIOTTI, ENNIO;SAKAMOTO, JASON;REEL/FRAME:020377/0154

Effective date: 20070918

AS Assignment

Owner name: US GOVERNMENT - SECRETARY FOR THE ARMY, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER HOUSTON;REEL/FRAME:020849/0735

Effective date: 20080116

AS Assignment

Owner name: NASA, DISTRICT OF COLUMBIA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:TEXAS HEALTH SCIENCE CENTER AT HOUSTON, UNIVERSITY OF;REEL/FRAME:022576/0736

Effective date: 20090204

Owner name: NASA, DISTRICT OF COLUMBIA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON;REEL/FRAME:022576/0748

Effective date: 20090204

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION